<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b62c0b44-b534-4364-8776-811b0df198ba"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">DAPZURA RT</content> safely and effectively.  See full prescribing information for <content styleCode="bold">DAPZURA RT</content>.<br/>
      <content styleCode="bold">DAPZURA RT (daptomycin for injection), for Intravenous use<br/>
      </content>Initial U.S. Approval: 2003</title>
   <effectiveTime value="20220125"/>
   <setId root="cb1283e1-35b8-425c-b338-d9ac0c7161f8"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="caafe33a-1aa6-42ed-bfaa-54e1a4d178c0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220125"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60977-145" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DAPZURA RT</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daptomycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPTOMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NWQ5N31VKK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPTOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="238"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="238"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="60977-145-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20220125"/>
                                          <high value="20220125"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213645" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220125"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>pale yellow to light brown</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_fa1efd3e-c7f1-4dc0-be95-af6c70c261ba">
               <id root="fa1efd3e-c7f1-4dc0-be95-af6c70c261ba"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DAPZURA RT is a lipopeptide antibacterial indicated for the treatment of:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) (<linkHtml href="#ID_b19ebc1e-af47-4c96-8ae4-2aedb0c41f9b">1.1</linkHtml>) and, </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Staphylococcus aureus</content> bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, (<linkHtml href="#ID_115e9420-00ef-4ed2-a85d-4fb613413bd7">1.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Staphylococcus aureus</content> bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age).<content styleCode="italics"/>(<linkHtml href="#ID_56bcfc3f-6e71-40e4-8774-b396defc0e9f">1.3</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>DAPZURA RT is not indicated for the treatment of pneumonia. (<linkHtml href="#_1.4_Limitations_of">1.4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>DAPZURA RT is not indicated for the treatment of left-sided infective endocarditis due to <content styleCode="italics">S. aureus</content>. (<linkHtml href="#_1.4_Limitations_of">1.4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>DAPZURA RT is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. (<linkHtml href="#_1.4_Limitations_of">1.4</linkHtml>) </item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of DAPZURA RT and other antibacterial drugs, DAPZURA RT should be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#ID_8c9d87c3-c461-48a9-bb60-f5cdbc256d05">1.5</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_b19ebc1e-af47-4c96-8ae4-2aedb0c41f9b">
                     <id root="b19ebc1e-af47-4c96-8ae4-2aedb0c41f9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Complicated Skin and Skin Structure Infections (cSSSI) </title>
                     <text>
                        <paragraph>DAPZURA RT is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_115e9420-00ef-4ed2-a85d-4fb613413bd7">
                     <id root="115e9420-00ef-4ed2-a85d-4fb613413bd7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 <content styleCode="italics">Staphylococcus aureus</content> Bloodstream Infections (Bacteremia) in Adult Patients, Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates </title>
                     <text>
                        <paragraph>DAPZURA RT is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_56bcfc3f-6e71-40e4-8774-b396defc0e9f">
                     <id root="56bcfc3f-6e71-40e4-8774-b396defc0e9f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Staphylococcus aureus Bloodstream Infections (Bacteremia) in Pediatric Patients (1 to 17 Years of Age) </title>
                     <text>
                        <paragraph>DAPZURA RT is indicated for the treatment of pediatric patients (1 to 17 years of age) with Staphylococcus aureus bloodstream infections (bacteremia).</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8c9d87c3-c461-48a9-bb60-f5cdbc256d05">
                     <id root="8c9d87c3-c461-48a9-bb60-f5cdbc256d05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Limitations of Use   </title>
                     <text>
                        <paragraph>DAPZURA RT is not indicated for the treatment of pneumonia. </paragraph>
                        <paragraph>DAPZURA RT is not indicated for the treatment of left-sided infective endocarditis due to <content styleCode="italics">S. aureus</content>. The clinical trial of daptomycin for injection in adult patients with <content styleCode="italics">S. aureus</content> bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor <content styleCode="italics">[see <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">Clinical Studies (14.2)</linkHtml>].</content> Daptomycin for injection has not been studied in patients with prosthetic valve endocarditis. </paragraph>
                        <paragraph>DAPZURA RT is not recommended in pediatric patients younger than 1 year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs <content styleCode="italics">[see <linkHtml href="#ID_0688ad22-89e9-4a52-8dbb-d82e751d2d84">Warnings and Precautions (5.7)</linkHtml> and <linkHtml href="#ID_0122b958-2bd3-4896-b78d-73125ad01158">Nonclinical Toxicology (13.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3471e968-aa69-4db4-8c1d-f3dfbd6cc8a4">
                     <id root="3471e968-aa69-4db4-8c1d-f3dfbd6cc8a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5 Usage </title>
                     <text>
                        <paragraph>Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. </paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of DAPZURA RT and other antibacterial drugs, DAPZURA RT should be used only to prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. </paragraph>
                        <paragraph>When culture and susceptibility information is available, it should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_09832a56-8055-416e-9b61-97d97cce521c">
               <id root="7249ce4a-8330-472c-aa70-f65e90bb21c8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer to <content styleCode="bold">adult patients</content> intravenously in 0.9% sodium chloride, either by injection over a 2-minute period or by infusion over a 30-minute period. (<linkHtml href="#ID_48bd51af-3771-45dd-b5e7-4337cf94063d">2.1</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Recommended dosage regimen for adult patients (<linkHtml href="#ID_ed292ea6-43e8-4341-8559-1d2d5e1a2068">2.2</linkHtml>, <linkHtml href="#ID_9354d954-7ee9-4a97-9afa-7637d62cfc4d">2.4</linkHtml>, <linkHtml href="#ID_4537c9db-b2c3-4de6-b7bf-800fb5dfdfee">2.6</linkHtml>):</item>
                        </list>
                        <table styleCode="Noautorules" width="100%">
                           <col width="44%"/>
                           <col width="28%"/>
                           <col width="28%"/>
                           <thead>
                              <tr>
                                 <th align="left" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Creatinine Clearance<br/>(CL<sub>CR</sub>)</th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage Regimen</th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <content styleCode="underline">cSSSI</content>
                                    <br/>For 7 to 14 days</th>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <content styleCode="underline">
                                       <content styleCode="italics">S. aureus </content>Bacteremia</content>
                                    <br/>For 2 to 6 weeks</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>≥30 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4 mg/kg once every 24 hours</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 mg/kg once every 24 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>&lt;30 mL/min, including hemodialysis and CAPD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>4 mg/kg once every 48 hours<footnote ID="_Ref43067349">Administered following hemodialysis on hemodialysis days.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>6 mg/kg once every 48 hours<footnoteRef IDREF="_Ref43067349"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Unlike in adults, do NOT administer by injection over a two (2) minute period to pediatric patients.</content> (<linkHtml href="#ID_48bd51af-3771-45dd-b5e7-4337cf94063d">2.1</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Administer to pediatric patients intravenously in 0.9% sodium chloride, by infusion over a 30- or 60-minute period, based on age. (<linkHtml href="#ID_48bd51af-3771-45dd-b5e7-4337cf94063d">2.1</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Recommended dosage regimen for pediatric patients (1 to 17 years of age) with cSSSI, based on age (<linkHtml href="#ID_1f13b476-39c3-4315-a546-766e3b7ee169">2.3</linkHtml>):</item>
                        </list>
                        <table width="100%">
                           <col width="22%"/>
                           <col width="53%"/>
                           <col width="20%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Age group</th>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage<footnote ID="_Ref43339308">Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established.</footnote>
                                 </th>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Duration of therapy</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                                 <td rowspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Up to 14 days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 to 6 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>1 to less than 2 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>10 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Recommended dosage regimen for pediatric patients (1 to 17 years of age) with <content styleCode="italics">S. aureus </content>bacteremia, based on age (<linkHtml href="#ID_a16cd607-fe8d-4361-9eb3-176727025bb6">2.5</linkHtml>):</item>
                        </list>
                        <table width="100%">
                           <col width="15%"/>
                           <col width="53%"/>
                           <col width="20%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Age group</th>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage<footnote ID="_Ref43339339">Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established.</footnote>
                                 </th>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Duration of therapy</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                                 <td rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Up to 42 days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1 to 6 years</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>There are other formulations of daptomycin that have differences concerning storage and reconstitution. Carefully follow the reconstitution and storage procedures described in this labeling. (<linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Do not use in conjunction with ReadyMED<sup>® </sup>elastomeric infusion pumps in adult and pediatric patients. (<linkHtml href="#ID_2d223cbd-3db6-4499-9f21-453fa80d8137">2.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_48bd51af-3771-45dd-b5e7-4337cf94063d">
                     <id root="4f9e4930-7a12-4cd6-8b16-3c180bca0ff9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Duration Instructions   </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>Administer the appropriate volume of the reconstituted DAPZURA RT (concentration of 50 mg/mL) <content styleCode="bold">to adult patients</content> intravenously either by injection over a two (2) minute period or by intravenous infusion over a thirty (30) minute period <content styleCode="italics">[see <linkHtml href="#ID_ed292ea6-43e8-4341-8559-1d2d5e1a2068">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#ID_9354d954-7ee9-4a97-9afa-7637d62cfc4d">2.4</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (1 to 17 Years of Age)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Unlike in adults, do NOT administer</content> DAPZURA RT <content styleCode="bold">by injection over a two (2) minute period to pediatric patients.</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Pediatric Patients 7 to 17 years of Age: Administer DAPZURA RT intravenously by infusion over a 30-minute period <content styleCode="italics">[see <linkHtml href="#ID_1f13b476-39c3-4315-a546-766e3b7ee169">Dosage and Administration (2.3</linkHtml>, <linkHtml href="#ID_a16cd607-fe8d-4361-9eb3-176727025bb6">2.5</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>•</caption>Pediatric Patients 1 to 6 years of Age: Administer DAPZURA RT intravenously by infusion over a 60-minute period <content styleCode="italics">[see <linkHtml href="#ID_1f13b476-39c3-4315-a546-766e3b7ee169">Dosage and Administration (2.3</linkHtml>, <linkHtml href="#ID_a16cd607-fe8d-4361-9eb3-176727025bb6">2.5</linkHtml>, <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">2.7</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ed292ea6-43e8-4341-8559-1d2d5e1a2068">
                     <id root="ed292ea6-43e8-4341-8559-1d2d5e1a2068"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage in Adults for cSSSI  </title>
                     <text>
                        <paragraph>Administer DAPZURA RT  4 mg/kg to adult patients intravenously once every 24 hours for 7 to 14 days.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1f13b476-39c3-4315-a546-766e3b7ee169">
                     <id root="01cb8c3b-6c99-4eaf-ab0c-8d37c1ccddd4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3   Dosage in Pediatric Patients (1 to 17 Years of Age) for cSSSI </title>
                     <text>
                        <paragraph>The recommended dosage regimens based on age for pediatric patients with cSSSI are shown in <linkHtml href="#_Ref95296190">Table 1</linkHtml>. Administer DAPZURA RT intravenously once every 24 hours for up to 14 days.</paragraph>
                        <table ID="_Ref95296190" width="550.8pt">
                           <caption>Table 1. Recommended Dosage of DAPZURA RT in Pediatric Patients (1 to 17 Years of Age) with cSSSI, Based on Age</caption>
                           <col width="23%"/>
                           <col width="54%"/>
                           <col width="23%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Age Range</th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage Regimen<footnote ID="_Ref95306943">Recommended dosage regimen is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established.</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Duration of therapy</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                                 <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Up to 14 days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 to 6 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1 to less than 2 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>10 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9354d954-7ee9-4a97-9afa-7637d62cfc4d">
                     <id root="9354d954-7ee9-4a97-9afa-7637d62cfc4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage in Adult Patients with <content styleCode="italics">Staphylococcus aureus</content> Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates </title>
                     <text>
                        <paragraph>Administer DAPZURA RT 6 mg/kg to adult patients intravenously once every 24 hours for 2 to 6 weeks. There are limited safety data for the use of daptomycin for injection for more than 28 days of therapy. In the Phase 3 trial, there were a total of 14 adult patients who were treated with daptomycin for injection for more than 28 days.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a16cd607-fe8d-4361-9eb3-176727025bb6">
                     <id root="4c50588f-f19b-4bc8-9c05-ec36ac358fe1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage in Pediatric Patients (1 to 17 Years of Age) with <content styleCode="italics">Staphylococcus aureus</content> Bloodstream Infections (Bacteremia)  </title>
                     <text>
                        <paragraph>The recommended dosage regimens based on age for pediatric patients with S. aureus bloodstream infections (bacteremia) are shown in <linkHtml href="#_Ref95296227">Table 2</linkHtml>. Administer DAPZURA RT  intravenously in 0.9% sodium chloride injection once every 24 hours for up to 42 days.</paragraph>
                        <table ID="_Ref95296227" width="100%">
                           <caption>Table 2. Recommended Dosage of DAPZURA RT in Pediatric Patients (1 to 17 Years of Age) with S. aureus Bacteremia, Based on Age</caption>
                           <col width="15%"/>
                           <col width="53%"/>
                           <col width="20%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Age group</th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage<footnote ID="_Ref95296126">Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage adjustment for pediatric patients with renal impairment has not been established.</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Duration of therapy</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Up to 42 days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9 mg/kg once every 24 hours infused over 30 minutes</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1 to 6 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12 mg/kg once every 24 hours infused over 60 minutes</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4537c9db-b2c3-4de6-b7bf-800fb5dfdfee">
                     <id root="459ed9c5-01f3-4b4e-b5cf-08b09e79d624"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage in Patients with Renal Impairment </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients:</content>
                        </paragraph>
                        <paragraph>No dosage adjustment is required in adult patients with creatinine clearance (CLCR) greater than or equal to 30 mL/min. The recommended dosage regimen for DAPZURA RT  in adult patients with CLCR less than 30 mL/min, including adult patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), is 4 mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hours (<linkHtml href="#_Ref95296357">Table 3</linkHtml>). When possible, DAPZURA RT should be administered following the completion of hemodialysis on hemodialysis days <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_1c666332-2cd6-4ce1-9d55-3ffb703581d2">5.10</linkHtml>), <linkHtml href="#ID_1f2c8cc7-8be0-48c7-99da-104861a35aca">Use in Specific Populations (8.6)</linkHtml>, and <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3</linkHtml>)].</content>
                        </paragraph>
                        <table ID="_Ref95296357" styleCode="Noautorules" width="100%">
                           <caption>Table 3. Recommended Dosage of DAPZURA RT in Adult Patients</caption>
                           <col width="46%"/>
                           <col width="25%"/>
                           <col width="29%"/>
                           <thead>
                              <tr>
                                 <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Creatinine Clearance<br/>(CLCR)</th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">Dosage Regimen in Adults</th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">cSSSI</th>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">S. aureus Bloodstream Infections</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Greater than or equal to 30 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4 mg/kg once every 24 hours</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>6 mg/kg once every 24 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Less than 30 mL/min, including hemodialysis and CAPD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>4 mg/kg once every 48 hours<footnote ID="_Ref95296393">When possible, administer DAPZURA RT following the completion of hemodialysis on hemodialysis days.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>6 mg/kg once every 48 hours<footnoteRef IDREF="_Ref95296393"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients:</content>
                        </paragraph>
                        <paragraph>The dosage regimen for DAPZURA RT in pediatric patients with renal impairment has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">
                     <id root="38b5d153-6c64-4805-ae54-9f382502c43a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Preparation and Administration of DAPZURA RT   </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">There are other formulations of daptomycin that have differences concerning reconstitution and storage. Carefully follow the reconstitution and storage procedures described in this labeling. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Reconstitution of DAPZURA RT Vial </content>
                        </paragraph>
                        <paragraph>DAPZURA RT must be reconstituted within the vial only with either Sterile Water for Injection or Bacteriostatic Water for Injection.  </paragraph>
                        <paragraph>Do <content styleCode="bold">NOT</content> use saline based diluents for the reconstitution in the vial because this will result in a hyperosmotic solution that may result in infusion site reactions if the reconstituted product is administered as an intravenous injection over a period of 2 minutes. </paragraph>
                        <paragraph>DAPZURA RT is supplied in single-dose vials, each containing 500 mg daptomycin as a sterile, lyophilized powder. The contents of a DAPZURA RT vial should be reconstituted, using aseptic technique, to 50 mg/mL as follows: </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Remove the polypropylene flip-off cap from the DAPZURA RT vial to expose the central portion of the rubber stopper. </item>
                           <item>
                              <caption>2.</caption>Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. </item>
                           <item>
                              <caption>3.</caption>Transfer 10 mL of Sterile Water for Injection or Bacteriostatic Water for Injection through the center of the rubber stopper into the DAPZURA RT vial. Use a beveled sterile transfer needle that is 21 gauge or smaller in diameter, pointing the transfer needle toward the wall of the vial. </item>
                           <item>
                              <caption>4.</caption>Rotate or swirl the vial contents for a few minutes, as needed, to obtain a completely reconstituted solution.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions </content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter prior to administration. </paragraph>
                        <paragraph>Slowly remove reconstituted liquid (50 mg daptomycin/mL) from the vial using a beveled sterile needle that is 21 gauge or smaller in diameter. Administer as an intravenous injection or infusion as described below: </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Intravenous Injection over a period of 2 minutes</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For intravenous (IV) injection over a period of 2 minutes in adult patients only: Administer the appropriate volume of the reconstituted DAPZURA RT (concentration of 50 mg/mL). </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Intravenous Infusion over a period of 30 minutes </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For IV infusion over a period of 30 minutes in adult patients: The appropriate volume of the reconstituted DAPZURA RT (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection. </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (1 to 17 Years of Age) </content>
                        </paragraph>
                        <paragraph>Intravenous Infusion over a period of 30 or 60 minutes </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Unlike in Adults, do NOT administer DAPZURA RT by injection over a two (2) minute period to pediatric patients </content>
                              <content styleCode="italics">[see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID_48bd51af-3771-45dd-b5e7-4337cf94063d">Dosage and Administration (2.1)</linkHtml>
                              </content>
                              <content styleCode="italics">].</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">For Intravenous infusion over a period of 60 minutes in pediatric patients 1 to 6 years of age:</content> The appropriate volume of the reconstituted DAPZURA RT (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into an intravenous infusion bag containing 25 mL of 0.9% sodium chloride injection. The infusion rate should be maintained at 0.42 mL/minute over the 60-minute period. </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">For Intravenous infusion over a period of 30 minutes in pediatric patients 7 to 17 years of age: </content>The appropriate volume of the reconstituted DAPZURA RT (concentration of 50 mg/mL) should be further diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection. The infusion rate should be maintained at 1.67 mL/minute over the 30-minute period. </item>
                        </list>
                        <paragraph>No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used in the preparation of final IV solution. <linkHtml href="#_Ref95296590">Table 4</linkHtml> below provides in-use storage conditions for reconstituted DAPZURA RT in acceptable intravenous diluents in the syringe, vial and intravenous bag (for reconstitution and dilution). Do not exceed the listed shelf-life of reconstituted and diluted solutions of DAPZURA RT. Discard unused portions of DAPZURA RT.</paragraph>
                        <table ID="_Ref95296590" width="100%">
                           <caption>Table 4. In-Use Storage Conditions for DAPZURA RT Once Reconstituted in Acceptable Intravenous Diluents</caption>
                           <col width="19%"/>
                           <col width="24%"/>
                           <col width="26%"/>
                           <col width="27%"/>
                           <thead>
                              <tr>
                                 <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Container</content>
                                 </th>
                                 <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Diluent</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">In-Use Shelf-Life</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <content styleCode="bold">Room Temperature</content>
                                    <br/>
                                    <content styleCode="bold">(20°C–25°C, 68°F–77°F)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <content styleCode="bold">Refrigerated</content>
                                    <br/>
                                    <content styleCode="bold">(2°C–8°C, 36°F–46°F)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Vial</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Sterile Water for Injection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>18 Hours</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3 Days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Bacteriostatic Water for Injection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2 Days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 Days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Syringe</content>
                                       <footnote ID="_Ref95296670">Polypropylene syringe with elastomeric plunger stopper.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Sterile Water for Injection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>18 Hours</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3 Days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Bacteriostatic Water for Injection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2 Days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 Days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Intravenous Bag</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Vial reconstituted with Sterile Water for Injection and immediately diluted with 0.9% sodium chloride.</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 Day</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3 Days</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Vial reconstituted with Bacteriostatic Water for Injection and immediately diluted with 0.9% sodium chloride injection.</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2 Days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>5 Days</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3e0e13eb-d5e7-422f-88ed-c9c40a80fe86">
                     <id root="5c69a1ab-cb94-465b-a7f7-1c00d1a2f988"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.8 Compatible Intravenous Solutions </title>
                     <text>
                        <paragraph>Reconstituted DAPZURA RT is compatible with Sterile Water for Injection, Bacteriostatic Water for Injection, and 0.9% sodium chloride injection. <content styleCode="italics">[See <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">Dosage and Administration (2.7)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2d223cbd-3db6-4499-9f21-453fa80d8137">
                     <id root="2d223cbd-3db6-4499-9f21-453fa80d8137"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.9 Incompatibilities </title>
                     <text>
                        <paragraph>Daptomycin for injection is not compatible with dextrose-containing diluents.</paragraph>
                        <paragraph>DAPZURA RT should not be used in conjunction with ReadyMED® elastomeric infusion</paragraph>
                        <paragraph>pumps. Stability studies of daptomycin for injection solutions stored in ReadyMED®</paragraph>
                        <paragraph>elastomeric infusion pumps identified an impurity (2-mercaptobenzothiazole) leaching</paragraph>
                        <paragraph>from this pump system into the daptomycin for injection solution.</paragraph>
                        <paragraph>Because only limited data are available on the compatibility of daptomycin for injection with other IV substances, additives and other medications should not be added to DAPZURA RT single-dose vials or infusion bags, or infused simultaneously with DAPZURA RT through the same IV line. If the same IV line is used for sequential infusion of different drugs, the line should be flushed with a compatible intravenous solution before and after infusion with DAPZURA RT.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_79acf09a-5fc1-4d0c-b69b-a68a0cc3bec0">
               <id root="79acf09a-5fc1-4d0c-b69b-a68a0cc3bec0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>For Injection: 500 mg daptomycin as a sterile, pale yellow to light brown lyophilized powder for reconstitution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Injection: 500 mg lyophilized powder for reconstitution in a single-dose vial (<linkHtml href="#ID_79acf09a-5fc1-4d0c-b69b-a68a0cc3bec0">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_2e1b05cc-e0e4-4ee2-a233-d7f993f6ce74">
               <id root="3add2655-e3a1-4c26-8992-5da0f5c3d8f0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>DAPZURA RT is contraindicated in:</paragraph>
                  <paragraph>•	 Patients with known hypersensitivity to daptomycin <content styleCode="italics">[see <linkHtml href="#ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
                  <list listType="ordered">
                     <item>
                        <caption> </caption>•	Patients with known or suspected Hereditary Fructose Intolerance (HFI) <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">Warnings and Precautions (5.11)</linkHtml>
                        </content>
                        <content styleCode="italics">].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Known hypersensitivity to daptomycin (<linkHtml href="#ID_2e1b05cc-e0e4-4ee2-a233-d7f993f6ce74">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Known or suspected Hereditary Fructose Intolerance (HFI) (<linkHtml href="#ID_2e1b05cc-e0e4-4ee2-a233-d7f993f6ce74">4,</linkHtml>
                              <linkHtml href="#ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_3d971618-a103-4050-bd47-573ed60cd559">
               <id root="2814bd9c-234a-4663-aa55-249654fa24d9"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Anaphylaxis/hypersensitivity reactions (including life-threatening): Discontinue DAPZURA RT<content styleCode="bold"/>and treat signs/symptoms. (<linkHtml href="#ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Myopathy and rhabdomyolysis: Monitor CPK levels and follow muscle pain or weakness; if elevated CPK or myopathy occurs, consider discontinuation of DAPZURA RT. (<linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">5.2</linkHtml>)  </item>
                           <item>
                              <caption>•</caption>Eosinophilic pneumonia: Discontinue DAPZURA RT<content styleCode="bold"/>and consider treatment with systemic steroids. (<linkHtml href="#ID_c66c6a0f-8070-42d0-b46e-29a9161999b5">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue DAPZURA RT<content styleCode="bold"/>and institute appropriate treatment. (<linkHtml href="#ID_34392483-c75a-4134-88d5-b319eb7e75e7">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Tubulointerstitial Nephritis (TIN): Discontinue DAPZURA RT<content styleCode="bold"/>and institute appropriate treatment. (<linkHtml href="#ID_f031b9f5-753e-4827-9e0f-1249ff472e3e">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Peripheral neuropathy: Monitor for neuropathy and consider discontinuation. (<linkHtml href="#ID_318fce59-5f18-4f7c-b8b4-71cc4637d396">5.6</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Potential nervous system and/or muscular system effects in pediatric patients younger than 12 months: Avoid use of <content styleCode="bold"/>DAPZURA RT in this age group. (<linkHtml href="#ID_0688ad22-89e9-4a52-8dbb-d82e751d2d84">5.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Clostridioides difficile–</content>associated diarrhea: Evaluate patients if diarrhea occurs. (<linkHtml href="#ID_18653154-083c-4ed0-8fb7-bd1c154a8030">5.8</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis: Perform susceptibility testing and rule out sequestered foci of infection. (<linkHtml href="#ID_1ff93b2d-d382-4305-bd5d-25eeac00411f">5.9</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Decreased efficacy was observed in adult patients with moderate baseline renal impairment. (<linkHtml href="#ID_1c666332-2cd6-4ce1-9d55-3ffb703581d2">5.10</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Hereditary Fructose Intolerance (HFI): DAPZURA RT contains sorbitol. Risk of metabolic crisis with life-threatening hypoglycemia, hypophosphatemia, lactic acidosis, and hepatic failure. Obtain history of HFI symptoms in pediatric patients before DAPZURA RT administration (<linkHtml href="#ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">5.11</linkHtml>, <linkHtml href="#ID_3fafda75-a072-4fe8-a573-d4bea83665b7">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">
                     <id root="b6d399f6-28e0-427c-8344-f24b6f376e5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Anaphylaxis/Hypersensitivity Reactions   </title>
                     <text>
                        <paragraph>Anaphylaxis/hypersensitivity reactions have been reported with the use of antibacterial agents, including daptomycin for injection, and may be life-threatening. If an allergic reaction to DAPZURA RT occurs, discontinue the drug and institute appropriate therapy <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c061bf68-533b-412a-b863-c46a029cd062">
                     <id root="090c7439-306b-4800-8209-506b7d814a24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Myopathy and Rhabdomyolysis </title>
                     <text>
                        <paragraph>Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), has been reported with the use of daptomycin for injection. Rhabdomyolysis, with or without acute renal failure, has been reported <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>Patients receiving DAPZURA RT should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. In patients who receive DAPZURA RT, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with DAPZURA RT. </paragraph>
                        <paragraph>In adult patients with renal impairment, both renal function and CPK should be monitored more frequently than once weekly <content styleCode="italics">[see <linkHtml href="#ID_1f2c8cc7-8be0-48c7-99da-104861a35aca">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>In Phase 1 studies and Phase 2 clinical trials in adults, CPK elevations appeared to be more frequent when daptomycin for injection was dosed more than once daily. Therefore, DAPZURA RT should not be dosed more frequently than once a day. </paragraph>
                        <paragraph>DAPZURA RT should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevations to levels &gt;1,000 U/L (~5× ULN), and in patients without reported symptoms who have marked elevations in CPK, with levels &gt;2,000 U/L (≥10× ULN). In addition, consideration should be given to suspending agents associated with rhabdomyolysis, such as HMG-CoA reductase inhibitors, temporarily in patients receiving DAPZURA RT <content styleCode="italics">[see <linkHtml href="#ID_6f4cb64b-8f06-4ee2-bfc0-fd1949d752f1">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c66c6a0f-8070-42d0-b46e-29a9161999b5">
                     <id root="b2fd260c-8c9c-4ae3-a4f3-c6f4355a2bc1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Eosinophilic Pneumonia </title>
                     <text>
                        <paragraph>Eosinophilic pneumonia has been reported in patients receiving daptomycin for injection<content styleCode="italics"> [see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>].</content> In reported cases associated with daptomycin for injection, patients developed fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia. In general, patients developed eosinophilic pneumonia 2 to 4 weeks after starting daptomycin for injection and improved when daptomycin for injection was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving DAPZURA RT should undergo prompt medical evaluation, and DAPZURA RT should be discontinued immediately. Treatment with systemic steroids is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_34392483-c75a-4134-88d5-b319eb7e75e7">
                     <id root="f4f4c1f6-cabf-4bd8-a637-85775c333247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) </title>
                     <text>
                        <paragraph>DRESS has been reported in post-marketing experience with daptomycin for injection  <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>]</content>. Patients who develop skin rash, fever, peripheral eosinophilia, and systemic organ (for example, hepatic, renal, pulmonary) impairment while receiving DAPZURA RT should undergo medical evaluation. If DRESS is suspected, discontinue DAPZURA RT promptly and institute appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f031b9f5-753e-4827-9e0f-1249ff472e3e">
                     <id root="95e48680-6e8d-4a16-b66d-ec0d5e78a426"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Tubulointerstitial Nephritis (TIN) </title>
                     <text>
                        <paragraph>TIN has been reported in post-marketing experience with daptomycin for injection  <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>]</content>. Patients who develop new or worsening renal impairment while receiving DAPZURA RT should undergo medical evaluation. If TIN is suspected, discontinue DAPZURA RT promptly and institute appropriate treatment<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_318fce59-5f18-4f7c-b8b4-71cc4637d396">
                     <id root="af5247b6-f86c-4fb9-8a4f-a65e56618aac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Peripheral Neuropathy   </title>
                     <text>
                        <paragraph>Cases of peripheral neuropathy have been reported during the daptomycin for injection postmarketing experience <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>].</content> Therefore, physicians should be alert to signs and symptoms of peripheral neuropathy in patients receiving DAPZURA RT. Monitor for neuropathy and consider discontinuation.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0688ad22-89e9-4a52-8dbb-d82e751d2d84">
                     <id root="0688ad22-89e9-4a52-8dbb-d82e751d2d84"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Potential Nervous System and/or Muscular System Effects in Pediatric Patients Younger than 12 Months </title>
                     <text>
                        <paragraph>Avoid use of DAPZURA RT<content styleCode="bold"/>in pediatric patients younger than 12 months due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs with intravenous daptomycin <content styleCode="italics">[see <linkHtml href="#ID_0122b958-2bd3-4896-b78d-73125ad01158">Nonclinical Toxicology (13.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_18653154-083c-4ed0-8fb7-bd1c154a8030">
                     <id root="c24d8527-a937-43b7-95ae-dc47a4a5e367"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>–associated diarrhea (CDAD) has been reported with the use of nearly all systemic antibacterial agents, including daptomycin for injection, and may range in severity from mild diarrhea to fatal colitis <content styleCode="italics">[see <linkHtml href="#ID_214d929a-bdd5-4781-bdb5-a0806147a095">Adverse Reactions (6.2)</linkHtml>].</content> Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <content styleCode="italics">C. difficile</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, since these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1ff93b2d-d382-4305-bd5d-25eeac00411f">
                     <id root="1ff93b2d-d382-4305-bd5d-25eeac00411f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Persisting or Relapsing <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis   </title>
                     <text>
                        <paragraph>Patients with persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis or poor clinical response should have repeat blood cultures. If a blood culture is positive for <content styleCode="italics">S. aureus</content>, minimum inhibitory concentration (MIC) susceptibility testing of the isolate should be performed using a standardized procedure, and diagnostic evaluation of the patient should be performed to rule out sequestered foci of infection. Appropriate surgical intervention (e.g., debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial regimen may be required. </paragraph>
                        <paragraph>Failure of treatment due to persisting or relapsing <content styleCode="italics">S. aureus</content> bacteremia/endocarditis may be due to reduced daptomycin susceptibility (as evidenced by increasing MIC of the <content styleCode="italics">S. aureus</content> isolate) <content styleCode="italics">[see <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">Clinical Studies (14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c666332-2cd6-4ce1-9d55-3ffb703581d2">
                     <id root="9c4e317f-167b-429b-95d3-697a7fd0a28c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Decreased Efficacy in Patients with Moderate Baseline Renal Impairment </title>
                     <text>
                        <paragraph>Limited data are available from the two Phase 3 complicated skin and skin structure infection (cSSSI) trials regarding clinical efficacy of daptomycin for injection treatment in adult patients with creatinine clearance (CL<sub>CR</sub>) &lt;50 mL/min; only 31/534 (6%) patients treated with daptomycin for injection in the intent-to-treat (ITT) population had a baseline CL<sub>CR</sub> &lt;50 mL/min. <linkHtml href="#_Ref95296808" title="Table 5">Table 5</linkHtml> shows the number of adult patients by renal function and treatment group who were clinical successes in the Phase 3 cSSSI trials.</paragraph>
                        <table ID="_Ref95296808" styleCode="Noautorules" width="100%">
                           <caption>Table 5. Clinical Success Rates by Renal Function and Treatment Group in Phase 3 cSSSI Trials in Adult Patients (Population: ITT)</caption>
                           <col width="25%"/>
                           <col width="50%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>CR</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Success Rate n/N (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection 4 mg/kg </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">every 24h</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>50- 70 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>25/38 (66%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30/48 (63%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>30-&lt;50 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7/15 (47%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>20/35 (57%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a subgroup analysis of the ITT population in the Phase 3 <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial, clinical success rates, as determined by a treatment-blinded Adjudication Committee <content styleCode="italics">[see <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">Clinical Studies (14.2)</linkHtml>]</content>, in the daptomycin for injection-treated adult patients were lower in patients with baseline CL<sub>CR</sub> &lt;50 mL/min (see <linkHtml href="#_Ref95296910" title="Table 6">Table 6</linkHtml>). A decrease of the magnitude shown in <linkHtml href="#_Ref95296910" title="Table 6">Table 6</linkHtml> was not observed in comparator-treated patients.</paragraph>
                        <table ID="_Ref95296910" styleCode="Noautorules" width="100%">
                           <caption>Table 6. Adjudication Committee Clinical Success Rates at Test of Cure by Baseline Creatinine Clearance and Treatment Subgroup in the S. aureus Bacteremia/Endocarditis Trial in Adult Patients (Population: ITT)</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Baseline CL<sub>CR</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Success Rate n/N (%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection 6 mg/kg every 24h</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Bacteremia</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Right-Sided</content>
                                       </item>
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Infective Endocarditis</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Bacteremia</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Right-Sided</content>
                                       </item>
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Infective Endocarditis</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>&gt;80 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30/50 (60%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7/14 (50%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>19/42 (45%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5/11 (46%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>50–80 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12/26 (46%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1/4 (25%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>13/31 (42%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1/2 (50%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>30–&lt;50 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2/14 (14%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0/1 (0%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7/17 (41%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1/1 (100%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Consider these data when selecting antibacterial therapy for use in adult patients with baseline moderate to severe renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">
                     <id root="3412f00f-64aa-455e-9500-b5e70916e25a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Risk in Patients with Hereditary Fructose Intolerance (HFI) </title>
                     <text>
                        <paragraph>DAPZURA RT contains sorbitol, an inactive ingredient, and may precipitate a metabolic crisis that may include, but is not limited to life-threatening hypoglycemia, hypophosphatemia, lactic acidosis, and hepatic failure in patients with HFI. The minimum amount of sorbitol at which serious adverse reactions may occur in these patients is not known.</paragraph>
                        <paragraph>Obtain a careful history of HFI symptoms (nausea, vomiting, abdominal pain) with sorbitol/fructose/sucrose exposure prior to DAPZURA RT administration because a diagnosis of HFI may not yet be established in pediatric patients <content styleCode="italics">[see <linkHtml href="#ID_2e1b05cc-e0e4-4ee2-a233-d7f993f6ce74">Contraindications (4)</linkHtml> and <linkHtml href="#ID_3fafda75-a072-4fe8-a573-d4bea83665b7">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f4e86019-e11e-4683-83eb-fde863bf1b74">
                     <id root="f4e86019-e11e-4683-83eb-fde863bf1b74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time </title>
                     <text>
                        <paragraph>Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay <content styleCode="italics">[see <linkHtml href="#ID_7394bb04-2293-4ac4-9565-9032ed45da2b">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_34aa47aa-54d7-4265-a858-609e577d6eaf">
                     <id root="34aa47aa-54d7-4265-a858-609e577d6eaf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Development of Drug-Resistant Bacteria </title>
                     <text>
                        <paragraph>Prescribing DAPZURA RT in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4866fcef-ebae-45bb-9802-550bbf7eb8f8">
               <id root="9e318b41-1d33-41d9-8200-c6991d8515da"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Anaphylaxis/Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Myopathy and Rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Eosinophilic Pneumonia <content styleCode="italics">[see <linkHtml href="#ID_c66c6a0f-8070-42d0-b46e-29a9161999b5">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Drug Reaction with Eosinophilia and Systemic Symptoms <content styleCode="italics">[see <linkHtml href="#ID_34392483-c75a-4134-88d5-b319eb7e75e7">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Tubulointerstitial Nephritis <content styleCode="italics">[see <linkHtml href="#ID_f031b9f5-753e-4827-9e0f-1249ff472e3e">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Peripheral Neuropathy <content styleCode="italics">[see <linkHtml href="#ID_318fce59-5f18-4f7c-b8b4-71cc4637d396">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time<content styleCode="italics"> [see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_f4e86019-e11e-4683-83eb-fde863bf1b74">Warnings and Precautions (5.12)</linkHtml>
                        </content>
                        <content styleCode="italics"> and <linkHtml href="#ID_7394bb04-2293-4ac4-9565-9032ed45da2b">Drug Interactions (7.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult cSSSI Patients:</content> The most common adverse reactions that occurred in ≥2% of adult cSSSI patients receiving daptomycin for injection 4 mg/kg were diarrhea, headache, dizziness, rash, abnormal liver function tests, elevated creatine phosphokinase (CPK), urinary tract infections, hypotension, and dyspnea. (<linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">6.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pediatric cSSSI Patients:</content> The most common adverse reactions that occurred in ≥2% of pediatric patients receiving daptomycin for injection were diarrhea, vomiting, abdominal pain, pruritus, pyrexia, elevated CPK, and headache. (<linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">6.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult <content styleCode="italics">S. aureus</content> bacteremia/endocarditis Patients:</content> The most common adverse reactions that occurred in ≥5% of <content styleCode="italics">S. aureus</content> bacteremia/endocarditis patients receiving daptomycin for injection 6 mg/kg were sepsis, bacteremia, abdominal pain, chest pain, edema, pharyngolaryngeal pain, pruritus, increased sweating, insomnia, elevated CPK, and hypertension. (<linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">6.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pediatric <content styleCode="italics">S. aureus</content> bacteremia Patients:</content> The most common adverse reactions that occurred in ≥5% of pediatric patients receiving daptomycin for injection were vomiting and elevated CPK. (<linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare Corporation at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">
                     <id root="9b33c8ed-94f4-4613-9615-56b30fbad91c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Clinical Trial Experience in Adult Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>Clinical trials enrolled 1,864 adult patients treated with daptomycin for injection and 1,416 treated with comparator. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Complicated Skin and Skin Structure Infection Trials in Adults</content>
                           </content>
                        </paragraph>
                        <paragraph>In Phase 3 complicated skin and skin structure infection (cSSSI) trials in adult patients, daptomycin for injection was discontinued in 15/534 (2.8%) patients due to an adverse reaction, while comparator was discontinued in 17/558 (3.0%) patients. </paragraph>
                        <paragraph>The rates of the most common adverse reactions, organized by body system, observed in adult patients with cSSSI (receiving 4 mg/kg daptomycin for injection) are displayed in <linkHtml href="#_Ref95297074" title="Table 7">Table 7</linkHtml>.</paragraph>
                        <table ID="_Ref95297074" width="100%">
                           <caption>Table 7. Incidence of Adverse Reactions that Occurred in ≥2% of Adult Patients in the Daptomycin for Injection Treatment Group and ≥ the Comparator Treatment Group in Phase 3 cSSSI Trials</caption>
                           <col width="28%"/>
                           <col width="27%"/>
                           <col width="22%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adult Patients (%)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection 4 </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">mg/kg (N=534)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnote ID="_Ref95297037">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                       <content styleCode="bold"> (N=558)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Diarrhea </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5.2 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4.3 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Nervous system disorders </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Headache </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5.4 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5.4 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Dizziness </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.2 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.0 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Skin/subcutaneous disorders </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Rash </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4.3 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.8 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Diagnostic investigations </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Abnormal liver function tests </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.0 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.6 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Elevated CPK </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.8 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.8 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Infections </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Urinary tract infections </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.4 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.5 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Vascular disorders </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hypotension </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2.4 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.4 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory disorders </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Dyspnea </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>2.1 </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>1.6 </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Drug-related adverse reactions (possibly or probably drug-related) that occurred in &lt;1% of adult patients receiving daptomycin for injection in the cSSSI trials are as follows: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole:</content> fatigue, weakness, rigors, flushing, hypersensitivity </paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood/Lymphatic System:</content> leukocytosis, thrombocytopenia, thrombocytosis, eosinophilia, increased International Normalized Ratio (INR)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular System:</content> supraventricular arrhythmia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Dermatologic System:</content> eczema</paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive System:</content> abdominal distension, stomatitis, jaundice, increased serum lactate dehydrogenase </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic/Nutritional System:</content> hypomagnesemia, increased serum bicarbonate, electrolyte disturbance </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal System:</content> myalgia, muscle cramps, muscle weakness, arthralgia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> vertigo, mental status change, paresthesia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses: </content>taste disturbance, eye irritation </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">
                                 <content styleCode="underline">S. aureus Bacteremia/Endocarditis Trial in Adults</content>
                              </content>
                           </item>
                        </list>
                        <paragraph>In the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial involving adult patients, daptomycin for injection was discontinued in 20/120 (16.7%) patients due to an adverse reaction, while comparator was discontinued in 21/116 (18.1%) patients. </paragraph>
                        <paragraph>Serious Gram-negative infections (including bloodstream infections) were reported in 10/120 (8.3%) daptomycin for injection-treated patients and 0/115 comparator-treated patients. Comparator-treated patients received dual therapy that included initial gentamicin for 4 days. Infections were reported during treatment and during early and late follow-up. Gram-negative infections included cholangitis, alcoholic pancreatitis, sternal osteomyelitis/mediastinitis, bowel infarction, recurrent Crohn’s disease, recurrent line sepsis, and recurrent urosepsis caused by a number of different Gram-negative bacteria. </paragraph>
                        <paragraph>The rates of the most common adverse reactions, organized by System Organ Class (SOC), observed in adult patients with <content styleCode="italics">S. aureus</content> bacteremia/endocarditis (receiving 6 mg/kg daptomycin for injection) are displayed in <linkHtml href="#_Ref95298431" title="Table 8">Table 8</linkHtml>.</paragraph>
                        <table ID="_Ref95298431" width="100%">
                           <caption>Table 8. Incidence of Adverse Reactions that Occurred in ≥5% of Adult Patients in the Daptomycin for Injection Treatment Group and ≥ the Comparator Treatment Group in the S. aureus Bacteremia/Endocarditis Trial</caption>
                           <col width="39%"/>
                           <col width="40%"/>
                           <col width="21%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <footnote ID="_Ref95297220">NOS, not otherwise specified.</footnote>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adult Patients </content>
                                    <br/>
                                    <content styleCode="bold"> n (%)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection 6 mg/kg (N=120)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnote ID="_Ref95297242">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV every 4h), each with initial low-dose gentamicin.</footnote>
                                       <content styleCode="bold">  (N=116)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Infections and infestations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Sepsis NOS</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 (5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3 (3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Bacteremia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 (5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0 (0%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Abdominal pain NOS</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4 (3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">General disorders and administration site conditions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Chest pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (7%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Edema NOS</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (7%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 (4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pharyngolaryngeal pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>10 (8%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 (5%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Sweating increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 (5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0 (0%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Insomnia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>11 (9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Investigations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Blood creatine phosphokinase increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (7%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Vascular disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Hypertension NOS</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7 (6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>3 (3%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following reactions, not included above, were reported as possibly or probably drug-related in the daptomycin for injection-treated group: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and Lymphatic System Disorders:</content> eosinophilia, lymphadenopathy, thrombocythemia, thrombocytopenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders:</content> atrial fibrillation, atrial flutter, cardiac arrest </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders</content>: tinnitus</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> vision blurred </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> dry mouth, epigastric discomfort, gingival pain, hypoesthesia oral </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations:</content> candidal infection NOS, vaginal candidiasis, fungemia, oral candidiasis, urinary tract infection fungal </paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> blood phosphorous increased, blood alkaline phosphatase increased, INR increased, liver function test abnormal, alanine aminotransferase increased, aspartate aminotransferase increased, prothrombin time prolonged </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition Disorders:</content> appetite decreased NOS </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> myalgia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> dyskinesia, paresthesia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders:</content> hallucination NOS </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content> proteinuria, renal impairment NOS </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> pruritus generalized, rash vesicular</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Other Trials in Adults</content>
                           </content>
                        </paragraph>
                        <paragraph>In Phase 3 trials of community-acquired pneumonia (CAP) in adult patients, the death rate and rates of serious cardiorespiratory adverse events were higher in daptomycin for injection-treated patients than in comparator-treated patients. These differences were due to lack of therapeutic effectiveness of daptomycin for injection in the treatment of CAP in patients experiencing these adverse events <content styleCode="italics">[see <linkHtml href="#_1.4_Limitations_of">Indications and Usage (1.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Laboratory Changes in Adults</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Complicated Skin and Skin Structure Infection Trials in Adults </content>
                        </paragraph>
                        <paragraph>In Phase 3 cSSSI trials of adult patients receiving daptomycin for injection at a dose of 4 mg/kg, elevations in CPK were reported as clinical adverse events in 15/534 (2.8%) daptomycin for injection-treated patients, compared with 10/558 (1.8%) comparator-treated patients. Of the 534 patients treated with daptomycin for injection, 1 (0.2%) had symptoms of muscle pain or weakness associated with CPK elevations to greater than 4 times the upper limit of normal (ULN). The symptoms resolved within 3 days and CPK returned to normal within 7 to 10 days after treatment was discontinued <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2)</linkHtml>]. </content>
                           <linkHtml href="#_Ref95298811" title="Table 9">Table 9</linkHtml> summarizes the CPK shifts from Baseline through End of Therapy in the cSSSI adult trials.</paragraph>
                        <table ID="_Ref95298811" width="99.22%">
                           <caption>Table 9. Incidence of CPK Elevations from Baseline during Therapy in Either the Daptomycin for Injection Treatment Group or the Comparator Treatment Group in Phase 3 cSSSI Adult Trials</caption>
                           <col width="29%"/>
                           <col width="10%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="8%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                                 <td align="center" colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">All Adult Patients</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Adult Patients with Normal CPK at Baseline</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Change in CPK</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection <br/>4 mg/kg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=430)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnote ID="_Ref95298529">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=459)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for <br/>Injection <br/>4 mg/kg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=374)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnoteRef IDREF="_Ref95298529"/>
                                       <content styleCode="bold">
                                          <br/>(N=392)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>No Increase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>90.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>390</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>91.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>418</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>91.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>341</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>91.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>357</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Maximum Value&gt;1× ULN<footnote ID="_Ref95298689">ULN (Upper Limit of Normal) is defined as 200 U/L.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>40</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>41</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>35</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>&gt;2× ULN</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>&gt;4× ULN</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>&gt;5× ULN</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>&gt;10× ULN</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="9" styleCode="Toprule " valign="middle">
                                    <paragraph>Note: Elevations in CPK observed in adult patients treated with daptomycin for injection or comparator were not clinically or statistically significantly different.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">S. aureus Bacteremia/Endocarditis Trial in Adults </content>
                        </paragraph>
                        <paragraph>In the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial in adult patients, at a dose of 6 mg/kg, 11/120 (9.2%) daptomycin for injection-treated patients, including two patients with baseline CPK levels &gt;500 U/L, had CPK elevations to levels &gt;500 U/L, compared with 1/116 (0.9%) comparator-treated patients. Of the 11 daptomycin for injection-treated patients, 4 had prior or concomitant treatment with an HMG-CoA reductase inhibitor. Three of these 11 daptomycin for injection-treated patients discontinued therapy due to CPK elevation, while the one comparator-treated patient did not discontinue therapy<content styleCode="italics"> [see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Clinical Trial Experience in Pediatric Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Complicated Skin and Skin Structure Infection Trial in Pediatric Patients</content>
                           </content>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>The safety of daptomycin for injection was evaluated in one clinical trial (in cSSSI), which included 256 pediatric patients (1 to 17 years of age) treated with intravenous daptomycin for injection and 133 patients treated with comparator agents. Patients were given age-dependent doses once daily for a treatment period of up to 14 days (median treatment period was 3 days). The doses given by age group were as follows: 10mg/kg for 1 to &lt; 2 years, 9 mg/kg for 2 to 6 years, 7mg/kg for 7 to 11 years and 5 mg/kg for 12 to 17 years of age <content styleCode="italics">[see <linkHtml href="#ID_42a77b39-cacd-4eaa-bd36-50ce950b0660">Clinical Studies (14)</linkHtml>]</content>. Patients treated with daptomycin for injection were (51%) male, (49%) female and (46%) Caucasian and (32%) Asian. <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation </content>
                        </paragraph>
                        <paragraph>In the cSSSI study, daptomycin for injection was discontinued in 7/256 (2.7%) patients due to an adverse reaction, while comparator was discontinued in 7/133 (5.3%) patients.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions </content>
                        </paragraph>
                        <paragraph>The rates of the most common adverse reactions, organized by body system, observed in these pediatric patients with cSSSI are displayed in <linkHtml href="#_Ref95298941" title="Table 10">Table 10</linkHtml>.</paragraph>
                        <table ID="_Ref95298941" width="100%">
                           <caption>Table 10. Adverse Reactions that Occurred in ≥2% of Pediatric Patients in the Daptomycin for Injection Treatment-Arm and Greater Than or Equal to the Comparator Treatment-Arm in the cSSSI Pediatric Trial</caption>
                           <col width="55%"/>
                           <col width="22%"/>
                           <col width="22%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Daptomycin for Injection (N = 256)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Comparator</content>
                                    <footnote ID="_Ref95298968">Comparators included intravenous therapy with either vancomycin, clindamycin, or an anti-staphylococcal semi-synthetic penicillin (nafcillin, oxacillin or cloxacillin)</footnote>
                                    <br/>
                                    <content styleCode="bold">(N = 133)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>18 (7.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (5.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (2.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1 (0.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Abdominal Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5 (2.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 (3.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2 (1.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">General disorders and administration site conditions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pyrexia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>10 (3.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4 (3.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Investigations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Blood CPK increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>14 (5.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7 (5.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Nervous system disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7 (2.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>3 (2.3)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The safety profile in the clinical trial of cSSSI pediatric patients was similar to that observed in the cSSSI adult patients. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">S. aureus Bacteremia Trial in Pediatric Patients</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety of daptomycin for injection was evaluated in one clinical trial (in <content styleCode="italics">S. aureus</content> bacteremia), which treated 55 pediatric patients with intravenous daptomycin for injection and 26 patients with comparator agents. Patients were given age-dependent doses once daily for a treatment period of up to 42 days (mean duration of IV treatment was 12 days). The doses by age group were as follows: 12 mg/kg for 1 to &lt;6 years, 9 mg/kg for 7 to 11 years and 7 mg/kg for 12 to 17 years of age <content styleCode="italics">[see <linkHtml href="#ID_42a77b39-cacd-4eaa-bd36-50ce950b0660">Clinical Studies (14)</linkHtml>]</content>. Patients treated with daptomycin for injection were (69%) male and (31%) female. No patients 1 to &lt;2 years of age were enrolled. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation</content>
                        </paragraph>
                        <paragraph>In the bacteremia study, daptomycin for injection was discontinued in 3/55 (5.5%) patients due to an adverse reaction, while comparator was discontinued in 2/26 (7.7%) patients.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions </content>
                        </paragraph>
                        <paragraph>The rates of the most common adverse reactions, organized by body system, observed in these pediatric patients with bacteremia are displayed in <linkHtml href="#_Ref95299093" title="Table 11">Table 11</linkHtml>.</paragraph>
                        <table ID="_Ref95299093" width="100%">
                           <caption>Table 11. Incidence of Adverse Reactions that Occurred in ≥5% of Pediatric Patients in the Daptomycin for Injection Treatment-Arm and Greater Than or Equal to the Comparator Treatment-Arm in the Pediatric Bacteremia Trial</caption>
                           <col width="39%"/>
                           <col width="29%"/>
                           <col width="32%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Daptomycin for Injection (N = 55)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Comparator (N = 26)</content>
                                    <footnote ID="_Ref95299339">Comparators included intravenous therapy with either vancomycin, cefazolin, or an anti-staphylococcal semi-synthetic penicillin (nafcillin, oxacillin or cloxacillin)</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6 (10.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2 (7.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Investigations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Blood CPK increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>4 (7.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_214d929a-bdd5-4781-bdb5-a0806147a095">
                     <id root="d1090e41-2104-4b3a-8619-ce18aac593f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-Marketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of daptomycin for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and lymphatic system disorders:</content> anemia, thrombocytopenia </paragraph>
                        <paragraph>
                           <content styleCode="italics">General and administration site conditions:</content> pyrexia<content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> anaphylaxis; hypersensitivity reactions, including angioedema, pruritus, hives, shortness of breath, difficulty swallowing, truncal erythema, and pulmonary eosinophilia <content styleCode="italics">[see <linkHtml href="#ID_2e1b05cc-e0e4-4ee2-a233-d7f993f6ce74">Contraindications (4)</linkHtml> and <linkHtml href="#ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">Warnings and Precautions (5.1)</linkHtml>] </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations: Clostridioides difficile</content>–associated diarrhea <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_18653154-083c-4ed0-8fb7-bd1c154a8030">Warnings and Precautions (5.8)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Laboratory Investigations:</content> platelet count decreased<content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal Disorders:</content> myoglobin increased; rhabdomyolysis (some reports involved patients treated concurrently with daptomycin for injection and HMG-CoA reductase inhibitors) <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#ID_6f4cb64b-8f06-4ee2-bfc0-fd1949d752f1">Drug Interactions (7.1)</linkHtml>, and <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content> cough, eosinophilic pneumonia, organizing pneumonia <content styleCode="italics">[see <linkHtml href="#ID_c66c6a0f-8070-42d0-b46e-29a9161999b5">Warnings and Precautions (5.3)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> peripheral neuropathy <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_318fce59-5f18-4f7c-b8b4-71cc4637d396">Warnings and Precautions (5.6)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> serious skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), vesiculobullous rash (with or without mucous membrane involvement, including Stevens-Johnson syndrome [SJS] and toxic epidermal necrolysis [TEN]), acute generalized exanthematous pustulosis <content styleCode="italics">[see <linkHtml href="#ID_34392483-c75a-4134-88d5-b319eb7e75e7">Warnings and Precautions (5.4)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> nausea, vomiting </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders:</content> acute kidney injury, renal insufficiency, renal failure, and tubulointerstitial nephritis (TIN) <content styleCode="italics">[see <linkHtml href="#ID_f031b9f5-753e-4827-9e0f-1249ff472e3e">Warnings and Precautions (5.5)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses:</content> visual disturbances</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f32f4ac6-0864-4f50-ad8f-75de1ad3c436">
               <id root="463da825-893d-4f2d-aca4-158a5f011d45"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="ID_6f4cb64b-8f06-4ee2-bfc0-fd1949d752f1">
                     <id root="562d0e71-1184-426f-a710-6b00ea393aa6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 HMG-CoA Reductase Inhibitors </title>
                     <text>
                        <paragraph>In healthy adult subjects, concomitant administration of daptomycin for injection and simvastatin had no effect on plasma trough concentrations of simvastatin, and there were no reports of skeletal myopathy <content styleCode="italics">[see <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>However, inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of creatine phosphokinase (CPK). In the adult Phase 3 <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial, some patients who received prior or concomitant treatment with an HMG-CoA reductase inhibitor developed elevated CPK <content styleCode="italics">[see <linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">Adverse Reactions (6.1)</linkHtml>].</content> Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving DAPZURA RT.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7394bb04-2293-4ac4-9565-9032ed45da2b">
                     <id root="7394bb04-2293-4ac4-9565-9032ed45da2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Drug-Laboratory Test Interactions </title>
                     <text>
                        <paragraph>Clinically relevant plasma concentrations of daptomycin have been observed to cause a significant concentration-dependent false prolongation of prothrombin time (PT) and elevation of International Normalized Ratio (INR) when certain recombinant thromboplastin reagents are utilized for the assay. The possibility of an erroneously elevated PT/INR result due to interaction with a recombinant thromboplastin reagent may be minimized by drawing specimens for PT or INR testing near the time of trough plasma concentrations of daptomycin. However, sufficient daptomycin concentrations may be present at trough to cause interaction. </paragraph>
                        <paragraph>If confronted with an abnormally high PT/INR result in a patient being treated with DAPZURA RT, it is recommended that clinicians: </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>12.</caption>Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next DAPZURA RT dose (i.e., at trough concentration). If the PT/INR value obtained at trough remains substantially elevated above what would otherwise be expected, consider evaluating PT/INR utilizing an alternative method. </item>
                           <item>
                              <caption>13.</caption>Evaluate for other causes of abnormally elevated PT/INR results.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d1df6286-bb54-435f-b13f-c0acc5f2bbba">
               <id root="ef9cabda-3f68-46ed-bb23-93e1c540160e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="ID_48d7c810-b8b6-4a36-aa48-4624d404878b">
                     <id root="0e0cb22e-448a-4538-8b3f-74e9f226e525"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published data on use of daptomycin for injection in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. In animal reproduction studies performed in rats and rabbits daptomycin was administered intravenously during organogenesis at doses 2 and 4–times, respectively, the recommended 6 mg/kg human dose (on a body surface area basis). No evidence of adverse developmental outcomes was observed. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. </paragraph>
                        <paragraph ID="Data">
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>In pregnant rats, daptomycin was administered intravenously at doses of 5, 20, or 75 mg/kg/day during the gestation days 6 to 18. Maternal body weight gain was decreased at 75 mg/kg/day. No embryo/fetal effects were noted at the highest dose of 75 mg/kg/day, a dose approximately 2-fold higher than in humans at the recommended maximum dose of 6 mg/kg (based on body surface area). </paragraph>
                        <paragraph>In pregnant rabbits, daptomycin was administered intravenously at doses of 5, 20, or 75 mg/kg/day during the gestation days 6 to 15. Maternal body weight gain and food consumption were decreased at 75 mg/kg/day. No embryo/fetal effects were noted at the highest dose of 75 mg/kg/day, a dose approximately 4-fold higher than in humans at the maximum recommended dose of 6 mg/kg (based on body surface area). </paragraph>
                        <paragraph>In a combined fertility and pre/postnatal development study, daptomycin was administered intravenously to female rats at doses of 2, 25, 75 mg/kg/day from 14-days pre-mating through lactation/postpartum day 20). No effects on pre/postnatal development were observed up to the highest dose of 75 mg/kg/day, a dose approximately 2-fold higher than the maximum recommended human dose of 6 mg/kg (based on body surface area)<sup>1</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d83627b4-b2e6-48ff-ae6c-f3c0aa5afb52">
                     <id root="d83627b4-b2e6-48ff-ae6c-f3c0aa5afb52"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Limited published data report that daptomycin is present in human milk at infant doses of 0.1% of the maternal dose <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml>]</content>
                           <sup>2,3,4</sup>. There is no information on the effects of daptomycin on the breastfed infant or the effects of daptomycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for daptomycin for injection and any potential adverse effects on the breastfed infant from daptomycin for injection or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3fafda75-a072-4fe8-a573-d4bea83665b7">
                     <id root="a028d21b-9084-4080-a69d-a194369a7fb2"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of daptomycin for injection in the treatment of cSSSI and <content styleCode="italics">S. aureus </content>bloodstream infections (bacteremia) have been established in the age groups 1 to 17 years of age. Use of daptomycin for injection in these age groups is supported by evidence from adequate and well-controlled studies in adults, with additional data from pharmacokinetic studies in pediatric patients, and from safety, efficacy and PK studies in pediatric patients with cSSSI and <content styleCode="italics">S. aureus </content>bloodstream infections<content styleCode="italics"> [see <linkHtml href="#ID_f10907ad-e495-426f-8ad1-9be9ff92eb40">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>, and </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_366d5972-d3b9-444e-b848-38e05e6e08cb">Clinical Studies (14.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of one year have not been established. Avoid use of DAPZURA RT in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs <content styleCode="italics">[see <linkHtml href="#ID_0688ad22-89e9-4a52-8dbb-d82e751d2d84">Warnings and Precautions (5.7)</linkHtml> and <linkHtml href="#ID_0122b958-2bd3-4896-b78d-73125ad01158">Nonclinical Toxicology (13.2)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>DAPZURA RT is not indicated in pediatric patients with renal impairment because dosage has not been established in these patients. </paragraph>
                        <paragraph>DAPZURA RT has not been studied in pediatric patients with other bacterial infections.  </paragraph>
                        <paragraph>DAPZURA RT is contraindicated in adult and pediatric patients with HFI. Because a diagnosis of HFI may not yet be established in pediatric patients, obtain a careful history of HFI symptoms with sorbitol/fructose/sucrose exposure prior to administration of DAPZURA RT <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">Warnings and Precautions (5.11)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7ce213c2-b254-4cee-9f6a-c09f06bcba67">
                     <id root="49e52ef1-ea6b-4d81-805c-db5af0d7ca99"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 534 adult patients treated with daptomycin for injection in Phase 3 controlled clinical trials of complicated skin and skin structure infections (cSSSI), 27% were 65 years of age or older and 12% were 75 years of age or older. Of the 120 adult patients treated with daptomycin for injection in the Phase 3 controlled clinical trial of <content styleCode="italics">S. aureus</content> bacteremia/endocarditis, 25% were 65 years of age or older and 16% were 75 years of age or older. In Phase 3 adult clinical trials of cSSSI and <content styleCode="italics">S. aureus</content> bacteremia/endocarditis, clinical success rates were lower in patients ≥65 years of age than in patients &lt;65 years of age. In addition, treatment-emergent adverse events were more common in patients ≥65 years of age than in patients &lt;65 years of age. </paragraph>
                        <paragraph>The exposure of daptomycin was higher in healthy elderly subjects than in healthy young adult subjects. However, no adjustment of DAPZURA RT dosage is warranted for elderly patients with creatinine clearance (CL<sub>CR</sub>) ≥30 mL/min <content styleCode="italics">[see <linkHtml href="#ID_4537c9db-b2c3-4de6-b7bf-800fb5dfdfee">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1f2c8cc7-8be0-48c7-99da-104861a35aca">
                     <id root="1f43ab7d-b526-4a8a-8f77-0d77b3f7c553"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Patients with Renal Impairment </title>
                     <text>
                        <paragraph>Daptomycin is eliminated primarily by the kidneys; therefore, a modification of DAPZURA RT dosage interval is recommended for adult patients with CL<sub>CR</sub> &lt;30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).  </paragraph>
                        <paragraph>In adult patients with renal impairment, both renal function and creatine phosphokinase (CPK) should be monitored more frequently than once weekly <content styleCode="italics">[see <linkHtml href="#ID_4537c9db-b2c3-4de6-b7bf-800fb5dfdfee">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2</linkHtml>, </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_1c666332-2cd6-4ce1-9d55-3ffb703581d2">5.10</linkHtml>
                           </content>
                           <content styleCode="italics">), and <linkHtml href="#ID_986afdfd-f962-444c-96a3-9ca38734f3f3">Clinical Pharmacology (12.3)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>The dosage regimen for DAPZURA RT in pediatric patients with renal impairment has not been established<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9ceba89d-be60-41b0-8918-10683b6f8f6f">
               <id root="9ceba89d-be60-41b0-8918-10683b6f8f6f"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>In the event of overdosage, supportive care is advised with maintenance of glomerular filtration. Daptomycin is cleared slowly from the body by hemodialysis (approximately 15% of the administered dose is removed over 4 hours) and by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours). The use of high-flux dialysis membranes during 4 hours of hemodialysis may increase the percentage of dose removed compared with that removed by low-flux membranes.</paragraph>
               </text>
               <effectiveTime value="20220125"/>
            </section>
         </component>
         <component>
            <section ID="ID_509c865b-37a1-4c80-b371-0afde657371c">
               <id root="956447bb-a207-4d8a-8413-81be7cc16de3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>DAPZURA RT (daptomycin for injection) contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of <content styleCode="italics">Streptomyces roseosporus</content>. The chemical name is <content styleCode="italics">N</content>-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-<content styleCode="italics">threo</content>-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine ℇ1-lactone. The chemical structure is:</paragraph>
                  <renderMultiMedia ID="id1972477515" referencedObject="ID_02b2b531-8cbe-446a-a2f9-8d28af443fe4"/>
                  <paragraph>The empirical formula is C<sub>72</sub>H<sub>101</sub>N<sub>17</sub>O<sub>26</sub>; the molecular weight is 1620.67. DAPZURA RT<content styleCode="bold"/>is supplied in a single-dose vial as a sterile, preservative-free, pale yellow to light brown, lyophilized powder containing 500 mg of daptomycin for intravenous (IV) use following reconstitution <content styleCode="italics">[see <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">Dosage and Administration (2.7)</linkHtml>].</content>  Each vial also contains 238 mg sorbitol and 238 mg of mannitol and sodium hydroxide and/or hydrochloric acid is used to adjust the pH. The pH of the solution upon reconstitution is 6.8. Freshly reconstituted solutions of DAPZURA RT range in color from pale yellow to light brown.</paragraph>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <observationMedia ID="ID_02b2b531-8cbe-446a-a2f9-8d28af443fe4">
                     <text>Daptomycin Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_78f912d2-9eb8-4d09-9b1b-8eaed9a0b327">
               <id root="8075aebd-96e6-4936-a22a-369dd2fa0597"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="ID_2702b0af-c79d-4dea-8a50-4adcea419d2f">
                     <id root="2702b0af-c79d-4dea-8a50-4adcea419d2f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Daptomycin is an antibacterial drug <content styleCode="italics">[see <linkHtml href="#_12.4_Microbiology">Clinical Pharmacology (12.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_99c7fa72-e5ad-43d2-823c-5f51c27556ce">
                     <id root="99c7fa72-e5ad-43d2-823c-5f51c27556ce"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain pathogens, including <content styleCode="italics">S. aureus</content>. The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with daptomycin for injection.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_986afdfd-f962-444c-96a3-9ca38734f3f3">
                     <id root="281b4a54-d626-49fa-9222-9ed2a061f1f5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Daptomycin for Injection Administered over a 30-Minute Period in Adults</content>
                        </paragraph>
                        <paragraph>The mean and standard deviation (SD) pharmacokinetic parameters of daptomycin at steady-state following intravenous (IV) administration of daptomycin for injection over a 30-minute period at 4 to 12 mg/kg every 24h to healthy young adults are summarized in .</paragraph>
                        <table width="100%">
                           <caption>Table 12. Mean (SD) Daptomycin Pharmacokinetic Parameters in Healthy Adult Volunteers at Steady-State</caption>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Dose</content>
                                    <footnote ID="_Ref95300036">Daptomycin for injection was administered by IV infusion over a 30-minute period.</footnote>
                                    <footnote ID="_Ref95300085">Doses of daptomycin for injection in excess of 6 mg/kg have not been approved.</footnote>
                                    <br/>
                                    <content styleCode="bold">(mg/kg)</content>
                                 </th>
                                 <th align="center" colspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Pharmacokinetic Parameters</content>
                                    <footnote ID="_Ref95300098">AUC0-24, area under the concentration-time curve from 0 to 24 hours; t1/2, elimination half-life; Vss, volume of distribution at steady-state; CLT, total plasma clearance; Cmax, maximum plasma concentration.</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>0-24</sub> (mcg•h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub> (h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>ss</sub> (L/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>T</sub> (mL/h/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub> (mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4 (N=6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>494 (75)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.1 (1.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.096 (0.009)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.3 (1.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>57.8 (3.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6 (N=6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>632 (78)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7.9 (1.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.101 (0.007)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9.1 (1.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>93.9 (6.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>8 (N=6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>858 (213)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.3 (2.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.101 (0.013)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9.0 (3.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>123.3 (16.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>10 (N=9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1039 (178)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7.9 (0.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.098 (0.017)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.8 (2.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>141.1 (24.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12 (N=9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1277 (253)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7.7 (1.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.097 (0.018)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>9.0 (2.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>183.7 (25.0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Daptomycin pharmacokinetics were generally linear and time-independent at daptomycin for injection doses of 4 to 12 mg/kg every 24h administered by IV infusion over a 30-minute period for up to 14 days. Steady-state trough concentrations were achieved by the third daily dose. The mean (SD) steady-state trough concentrations attained following the administration of 4, 6, 8, 10, and 12 mg/kg every 24h were 5.9 (1.6), 6.7 (1.6), 10.3 (5.5), 12.9 (2.9), and 13.7 (5.2) mcg/mL, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Daptomycin for Injection Administered over a 2-Minute Period in Adults</content>
                        </paragraph>
                        <paragraph>Following IV administration of daptomycin for injection over a 2-minute period to healthy adult volunteers at doses of 4 mg/kg (N=8) and 6 mg/kg (N=12), the mean (SD) steady-state systemic exposure (AUC) values were 475 (71) and 701 (82) mcg•h/mL, respectively. Values for maximum plasma concentration (C<sub>max</sub>) at the end of the 2-minute period could not be determined adequately in this study. However, using pharmacokinetic parameters from 14 healthy adult volunteers who received a single dose of daptomycin for injection 6 mg/kg IV administered over a 30-minute period in a separate study, steady-state C<sub>max</sub> values were simulated for daptomycin for injection 4 and 6 mg/kg IV administered over a 2-minute period. The simulated mean (SD) steady-state C<sub>max</sub> values were 77.7 (8.1) and 116.6 (12.2) mcg/mL, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranges from 90 to 93%. </paragraph>
                        <paragraph>In clinical studies, mean serum protein binding in adult subjects with creatinine clearance (CL<sub>CR</sub>) ≥30 mL/min was comparable to that observed in healthy adult subjects with normal renal function. However, there was a trend toward decreasing serum protein binding among subjects with CL<sub>CR</sub> &lt;30 mL/min (88%), including those receiving hemodialysis (86%) and continuous ambulatory peritoneal dialysis (CAPD) (84%). The protein binding of daptomycin in adult subjects with moderate hepatic impairment (Child-Pugh Class B) was similar to that in healthy adult subjects. </paragraph>
                        <paragraph>The volume of distribution at steady-state (V<sub>ss</sub>) of daptomycin in healthy adult subjects was approximately 0.1 L/kg and was independent of dose. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>In <content styleCode="italics">in vitro</content> studies, daptomycin was not metabolized by human liver microsomes. </paragraph>
                        <paragraph>In 5 healthy adults after infusion of radiolabeled <sup>14</sup>C-daptomycin, the plasma total radioactivity was similar to the concentration determined by microbiological assay. Inactive metabolites were detected in urine, as determined by the difference between total radioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites were observed in plasma on Day 1 following the administration of daptomycin for injection at 6 mg/kg to adult subjects. Minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Daptomycin is excreted primarily by the kidneys. In a mass balance study of 5 healthy adult subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations), and 5.7% of the administered dose was recovered from feces (collected for up to 9 days) based on total radioactivity. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment </content>
                        </paragraph>
                        <paragraph>Population-derived pharmacokinetic parameters were determined for infected adult patients (complicated skin and skin structure infections [cSSSI] and <content styleCode="italics">S. aureus</content> bacteremia) and noninfected adult subjects with various degrees of renal function (Table 13). Total plasma clearance (CL<sub>T</sub>), elimination half-life (t<sub>1/2</sub>), and volume of distribution at steady-state (V<sub>ss</sub>) in patients with cSSSI were similar to those in patients with <content styleCode="italics">S. aureus</content> bacteremia. Following administration of daptomycin for injection 4 mg/kg every 24h by IV infusion over a 30-minute period, the mean CL<sub>T</sub> was 9%, 22%, and 46% lower among subjects and patients with mild (CL<sub>CR</sub> 50– 80 mL/min), moderate (CL<sub>CR</sub> 30–&lt;50 mL/min), and severe (CL<sub>CR</sub> &lt;30 mL/min) renal impairment, respectively, than in those with normal renal function (CL<sub>CR</sub> &gt;80 mL/min). The mean steady-state systemic exposure (AUC), t<sub>1/2</sub>, and V<sub>ss</sub> increased with decreasing renal function, although the mean AUC for patients with CL<sub>CR</sub> 30–80 mL/min was not markedly different from the mean AUC for patients with normal renal function. The mean AUC for patients with CL<sub>CR</sub> &lt;30 mL/min and for patients on dialysis (CAPD and hemodialysis dosed post-dialysis) was approximately 2 and 3 times higher, respectively, than for patients with normal renal function. The mean C<sub>max</sub> ranged from 60 to 70 mcg/mL in patients with CL<sub>CR</sub> ≥30 mL/min, while the mean C<sub>max</sub> for patients with CL<sub>CR </sub>&lt;30 mL/min ranged from 41 to 58 mcg/mL. After administration of daptomycin for injection 6 mg/kg every 24h by IV infusion over a 30-minute period, the mean C<sub>max</sub> ranged from 80 to 114 mcg/mL in patients with mild to moderate renal impairment and was similar to that of patients with normal renal function.</paragraph>
                        <table width="100%">
                           <caption>Table 13. Mean (SD) Daptomycin Population Pharmacokinetic Parameters Following Infusion of Daptomycin for Injection 4 mg/kg or 6 mg/kg to Infected Adult Patients and Noninfected Adult Subjects with Various Degrees of Renal Function</caption>
                           <col width="21%"/>
                           <col width="12%"/>
                           <col width="11%"/>
                           <col width="15%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="12%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Renal Function</content>
                                 </th>
                                 <th align="center" colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Pharmacokinetic Parameters</content>
                                    <footnote ID="_Ref95303505">CL<sub>CR</sub>, creatinine clearance estimated using the Cockcroft-Gault equation with actual body weight; CAPD, continuous ambulatory peritoneal dialysis; AUC0-∞, area under the concentration-time curve extrapolated to infinity; AUCss, area under the concentration-time curve calculated over the 24-hour dosing interval at steady-state; Cmin,ss, trough concentration at steady-state; NA, not applicable.</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub>
                                       </content>
                                       <footnote ID="_Ref95303610">Parameters obtained following a single dose from patients with complicated skin and skin structure infections and healthy subjects.</footnote>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">4 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>ss</sub>
                                       </content>
                                       <footnoteRef IDREF="_Ref95303610"/>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(L/kg)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">4 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>T</sub>
                                       </content>
                                       <footnoteRef IDREF="_Ref95303610"/>
                                       <content styleCode="bold"> (mL/h/kg)</content>
                                       <br/>
                                       <content styleCode="bold">4 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>0-∞</sub>
                                       </content>
                                       <footnoteRef IDREF="_Ref95303610"/>
                                       <content styleCode="bold">(mcg•h/mL)</content>
                                       <br/>
                                       <content styleCode="bold">4 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>ss</sub>
                                       </content>
                                       <footnote ID="_Ref95303668">Parameters obtained at steady-state from patients with S. aureus bacteremia.</footnote>
                                       <content styleCode="bold">(mcg•h/mL)</content>
                                       <br/>
                                       <content styleCode="bold">6 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>min,ss</sub>
                                       </content>
                                       <footnoteRef IDREF="_Ref95303668"/>
                                       <content styleCode="bold">(mcg/mL)</content>
                                       <br/>
                                       <content styleCode="bold">6 mg/kg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Normal</paragraph>
                                    <paragraph>(CL<sub>CR</sub> &gt;80 mL/min)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9.39 (4.74)</paragraph>
                                    <paragraph>N=165</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.13 (0.05)</paragraph>
                                    <paragraph>N=165</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>10.9 (4.0)</paragraph>
                                    <paragraph>N=165</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>417 (155)</paragraph>
                                    <paragraph>N=165</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>545 (296)</paragraph>
                                    <paragraph>N=62</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6.9 (3.5)</paragraph>
                                    <paragraph>N=61</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Mild Renal</paragraph>
                                    <paragraph>Impairment</paragraph>
                                    <paragraph>(CL<sub>CR</sub> 50– 80 mL/min)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>10.75 (8.36)</paragraph>
                                    <paragraph>N=64</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.12 (0.05)</paragraph>
                                    <paragraph>N=64</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9.9 (4.0)</paragraph>
                                    <paragraph>N=64</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>466 (177)</paragraph>
                                    <paragraph>N=64</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>637 (215)</paragraph>
                                    <paragraph>N=29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12.4 (5.6)</paragraph>
                                    <paragraph>N=29</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Moderate Renal</paragraph>
                                    <paragraph>Impairment</paragraph>
                                    <paragraph>(CL<sub>CR</sub> 30– &lt;50 mL/min)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>14.70 (10.50)</paragraph>
                                    <paragraph>N=24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.15 (0.06)</paragraph>
                                    <paragraph>N=24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8.5 (3.4)</paragraph>
                                    <paragraph>N=24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>560 (258)</paragraph>
                                    <paragraph>N=24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>868 (349)</paragraph>
                                    <paragraph>N=15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>19.0 (9.0)</paragraph>
                                    <paragraph>N=14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Severe Renal Impairment</paragraph>
                                    <paragraph>(CL<sub>CR</sub> &lt;30 mL/min)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>27.83 (14.85)</paragraph>
                                    <paragraph>N=8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.20 (0.15)</paragraph>
                                    <paragraph>N=8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5.9 (3.9)</paragraph>
                                    <paragraph>N=8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>925 (467)</paragraph>
                                    <paragraph>N=8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1050 (892)</paragraph>
                                    <paragraph>N=2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>24.4</paragraph>
                                    <paragraph>(21.4)</paragraph>
                                    <paragraph>N=2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hemodialysis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30.51 (6.51)</paragraph>
                                    <paragraph>N=16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.16 (0.04)</paragraph>
                                    <paragraph>N=16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3.9 (2.1)</paragraph>
                                    <paragraph>N=16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1193 (399)</paragraph>
                                    <paragraph>N=16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>CAPD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>27.56 (4.53)</paragraph>
                                    <paragraph>N=5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.11 (0.02)</paragraph>
                                    <paragraph>N=5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2.9 (0.4)</paragraph>
                                    <paragraph>N=5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1409 (238)</paragraph>
                                    <paragraph>N=5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>NA</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="7" styleCode="Toprule " valign="middle">
                                    <paragraph>Note: Daptomycin for injection was administered over a 30-minute period.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Because renal excretion is the primary route of elimination, adjustment of DAPZURA RT<content styleCode="bold"/>dosage interval is necessary in adult patients with severe renal impairment (CL<sub>CR</sub> &lt;30 mL/min) <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_4537c9db-b2c3-4de6-b7bf-800fb5dfdfee">Dosage and Administration (2.6)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment  </content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of daptomycin were evaluated in 10 adult subjects with moderate hepatic impairment (Child-Pugh Class B) and compared with those in healthy adult volunteers (N=9) matched for gender, age, and weight. The pharmacokinetics of daptomycin were not altered in subjects with moderate hepatic impairment. No dosage adjustment is warranted when DAPZURA RT is administered to patients with mild to moderate hepatic impairment. The pharmacokinetics of daptomycin in patients with severe hepatic impairment (Child-Pugh Class C) have not been evaluated. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender </content>
                        </paragraph>
                        <paragraph>No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed. No dosage adjustment is warranted based on gender when DAPZURA RT<content styleCode="bold"/>is administered. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients </content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of daptomycin were evaluated in 12 healthy elderly subjects (≥75 years of age) and 11 healthy young adult controls (18 to 30 years of age). Following administration of a single 4 mg/kg dose of daptomycin for injection by IV infusion over a 30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean AUC<sub>0-∞</sub> was approximately 58% higher in elderly subjects than in healthy young adult subjects. There were no differences in C<sub>max </sub>
                           <content styleCode="italics">[see <linkHtml href="#ID_7ce213c2-b254-4cee-9f6a-c09f06bcba67">Use in Specific Populations (8.5)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Obese Patients  </content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of daptomycin were evaluated in 6 moderately obese (Body Mass Index [BMI] 25 to 39.9 kg/m<sup>2</sup>) and 6 extremely obese (BMI ≥40 kg/m<sup>2</sup>) adult subjects and controls matched for age, gender, and renal function. Following administration of daptomycin for injection by IV infusion over a 30-minute period as a single 4 mg/kg dose based on total body weight, the total plasma clearance of daptomycin normalized to total body weight was approximately 15% lower in moderately obese subjects and 23% lower in extremely obese subjects than in nonobese controls. The AUC<sub>0-∞</sub> of daptomycin was approximately 30% higher in moderately obese subjects and 31% higher in extremely obese subjects than in nonobese controls. The differences were most likely due to differences in the renal clearance of daptomycin. No adjustment of DAPZURA RT dosage is warranted in obese patients. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of daptomycin in pediatric subjects was evaluated in 3 single-dose pharmacokinetic studies. In general, body weight-normalized total body clearance in pediatric patients was higher than in adults and increased with a decrease of age, whereas elimination half-life tends to decrease with a decrease of age. Body weight-normalized total body clearance and elimination half-life of daptomycin in children 2 to 6 years of age were similar at different doses. </paragraph>
                        <paragraph>A study was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin in pediatric patients (1 to 17 years old, inclusive) with cSSSI caused by Gram-positive pathogens. Patients were enrolled into 4 age groups <content styleCode="italics">[see <linkHtml href="#ID_366d5972-d3b9-444e-b848-38e05e6e08cb">Clinical Studies (14.1)</linkHtml>]</content>, and intravenous daptomycin for injection doses of 5 to 10 mg/kg once daily were administered. Following administration of multiple doses, daptomycin exposure (AUC<sub>ss</sub> and C<sub>max,ss</sub>) was similar across different age groups after dose adjustment based on body weight and age (<linkHtml href="#_Ref95303770" title="Table 14">Table 14</linkHtml>).</paragraph>
                        <table ID="_Ref95303770" width="100%">
                           <caption>Table 14. Mean (SD) Daptomycin Population Pharmacokinetic Parameters in cSSSI Pediatric Patients</caption>
                           <col width="14%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="17%"/>
                           <col width="8%"/>
                           <col width="10%"/>
                           <col width="14%"/>
                           <col width="12%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Age</content>
                                 </th>
                                 <th align="center" colspan="7" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Pharmacokinetic Parameters</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dose (mg/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>
                                          <content styleCode="bold">Infusion</content>
                                       </item>
                                    </list>
                                    <paragraph>
                                       <content styleCode="bold">Duration</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(min)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>ss</sub> (mcg•h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>ss</sub> (mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>T</sub> (mL/h/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max,ss</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                    <paragraph>(N=6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>434 (67.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7.1 (0.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8200</paragraph>
                                    <paragraph>(3250)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>11.8 (2.15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>76.4 (6.75)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                    <paragraph>(N=2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>543<footnote ID="_Ref95303829">Mean is calculated from N=2</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6.8<footnoteRef IDREF="_Ref95303829"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4470<footnoteRef IDREF="_Ref95303829"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>13.2<footnoteRef IDREF="_Ref95303829"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>92.4<footnoteRef IDREF="_Ref95303829"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 to 6 years</paragraph>
                                    <paragraph>(N=7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>452 (93.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4.6 (0.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2750 (832)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>20.8 (4.29)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>90.3 (14.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 to less than 2 years</paragraph>
                                    <paragraph>(N=27)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>462 (138)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4.8 (0.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1670</paragraph>
                                    <paragraph>(446)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>23.1 (5.43)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>81.6 (20.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>AUC<sub>ss</sub>, area under the concentration-time curve at steady state; CL<sub>T</sub>, clearance normalized to body weight;  </paragraph>
                                    <paragraph>V<sub>ss</sub>, volume of distribution at steady state; t<sub>½</sub>, terminal half-life</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>A study was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin in pediatric patients with <content styleCode="italics">S. aureus </content>bacteremia. Patients were enrolled into 3 age groups <content styleCode="italics">[see <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">Clinical Studies (14.2)</linkHtml>]</content>, and intravenous doses of 7 to 12 mg/kg once daily were administered. Following administration of multiple doses, daptomycin exposure (AUC<sub>ss</sub> and C<sub>max,ss</sub>) was similar across different age groups after dose adjustment based on body weight and age (<linkHtml href="#_Ref95303942" title="Table 15">Table 15</linkHtml>).</paragraph>
                        <table ID="_Ref95303942" width="100%">
                           <caption>Table 15. Mean (SD) of Daptomycin Pharmacokinetics in Bacteremia Pediatric Patients</caption>
                           <col width="12%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="17%"/>
                           <col width="9%"/>
                           <col width="10%"/>
                           <col width="15%"/>
                           <col width="12%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Age</content>
                                 </th>
                                 <th align="center" colspan="7" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Pharmacokinetic Parameters</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dose </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mg/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Infusion</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Duration </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(min)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>ss</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg•h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2 </sub>(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">V<sub>ss</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>T</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mL/h/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max,ss</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 to 17 years</paragraph>
                                    <paragraph>(N=13)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>656 (334)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7.5 (2.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6420</paragraph>
                                    <paragraph>(1980)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12.4 (3.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>104 (35.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7 to 11 years</paragraph>
                                    <paragraph>(N=19)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>579 (116)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6.0 (0.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4510</paragraph>
                                    <paragraph>(1470)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>15.9 (2.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>104 (14.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 to 6 years</paragraph>
                                    <paragraph>(N=19)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>620 (109)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5.1 (0.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2200 (570)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>19.9 (3.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>106 (12.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>AUC<sub>ss</sub>, area under the concentration-time curve at steady state; CLT, clearance normalized to body weight; <br/>Vss, volume of distribution at steady state; t½, terminal half-life</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <br/>No patients 1 to &lt;2 years of age were enrolled in the study. Simulation using a population <br/>pharmacokinetic model demonstrated that the AUC<sub>ss </sub>of daptomycin in pediatric patients 1 to &lt;2 years of age receiving 12 mg/kg once daily would be comparable to that in adult patients receiving 6 mg/kg once daily.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs metabolized by the P450 system. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Aztreonam </content>
                        </paragraph>
                        <paragraph>In a study in which 15 healthy adult subjects received a single dose of daptomycin for injection 6 mg/kg IV and a combination dose of daptomycin for injection 6 mg/kg IV and aztreonam 1 g IV, administered over a 30-minute period, the C<sub>max</sub> and AUC<sub>0-∞</sub> of daptomycin were not significantly altered by aztreonam. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Tobramycin  </content>
                        </paragraph>
                        <paragraph>In a study in which 6 healthy adult males received a single dose of daptomycin for injection 2 mg/kg IV, tobramycin 1 mg/kg IV, and both in combination, administered over a 30-minute period, the mean C<sub>max </sub>and AUC<sub>0-∞</sub> of daptomycin were 12.7% and 8.7% higher, respectively, when daptomycin for injection was coadministered with tobramycin. The mean C<sub>max</sub> and AUC<sub>0-∞</sub> of tobramycin were 10.7% and 6.6% lower, respectively, when tobramycin was coadministered with daptomycin for injection. These differences were not statistically significant. The interaction between daptomycin and tobramycin with a clinical dose of DAPZURA RT is unknown. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Warfarin  </content>
                        </paragraph>
                        <paragraph>In 16 healthy adult subjects, administration of daptomycin for injection 6 mg/kg every 24h by IV infusion over a 30-minute period for 5 days, with coadministration of a single oral dose of warfarin (25 mg) on the 5th day, had no significant effect on the pharmacokinetics of either drug and did not significantly alter the INR (International Normalized Ratio). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Simvastatin </content>
                        </paragraph>
                        <paragraph>In 20 healthy adult subjects on a stable daily dose of simvastatin 40 mg, administration of daptomycin for injection 4 mg/kg every 24h by IV infusion over a 30-minute period for 14 days (N=10) had no effect on plasma trough concentrations of simvastatin and was not associated with a higher incidence of adverse events, including skeletal myopathy, than in subjects receiving placebo once daily (N=10) <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2)</linkHtml> and <linkHtml href="#ID_6f4cb64b-8f06-4ee2-bfc0-fd1949d752f1">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Probenecid  </content>
                        </paragraph>
                        <paragraph>Concomitant administration of probenecid (500 mg 4 times daily) and a single dose of daptomycin for injection 4 mg/kg by IV infusion over a 30-minute period in adults did not significantly alter the C<sub>max</sub> or AUC<sub>0-∞</sub> of daptomycin.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_865879ee-a875-46c2-8cf5-dc438d8099d7">
                     <id root="865879ee-a875-46c2-8cf5-dc438d8099d7"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>Daptomycin belongs to the cyclic lipopeptide class of antibacterials. Daptomycin has clinical utility in the treatment of infections caused by aerobic, Gram-positive bacteria. The <content styleCode="italics">in vitro</content> spectrum of activity of daptomycin encompasses most clinically relevant Gram-positive pathogenic bacteria.  </paragraph>
                        <paragraph>Daptomycin exhibits rapid, concentration-dependent bactericidal activity against Gram-positive bacteria <content styleCode="italics">in vitro</content>. This has been demonstrated both by time-kill curves and by MBC/MIC (minimum bactericidal concentration/minimum inhibitory concentration) ratios using broth dilution methodology. Daptomycin maintained bactericidal activity <content styleCode="italics">in vitro</content> against stationary phase <content styleCode="italics">S. aureus</content> in simulated endocardial vegetations. The clinical significance of this is not known. </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action </content>
                        </paragraph>
                        <paragraph>Daptomycin binds to bacterial cell membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of DNA, RNA, and protein synthesis, which results in bacterial cell death. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance  </content>
                        </paragraph>
                        <paragraph>The mechanism(s) of daptomycin resistance is not fully understood. Currently, there are no known transferable elements that confer resistance to daptomycin. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Interactions with Other Antibacterials </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies have investigated daptomycin interactions with other antibacterials. Antagonism, as determined by kill curve studies, has not been observed. <content styleCode="italics">In vitro</content> synergistic interactions of daptomycin with aminoglycosides, β-lactam antibacterials, and rifampin have been shown against some isolates of staphylococci (including some methicillin-resistant isolates) and enterococci (including some vancomycin-resistant isolates). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Complicated Skin and Skin Structure Infection (cSSSI) Trials in Adults  </content>
                        </paragraph>
                        <paragraph>The emergence of daptomycin non-susceptible isolates occurred in 2 infected patients across the set of Phase 2 and pivotal Phase 3 clinical trials of cSSSI in adult patients. In one case, a non-susceptible <content styleCode="italics">S. aureus</content> was isolated from a patient in a Phase 2 trial who received daptomycin for injection at less than the protocol-specified dose for the initial 5 days of therapy. In the second case, a non-susceptible <content styleCode="italics">Enterococcus faecalis</content> was isolated from a patient with an infected chronic decubitus ulcer who was enrolled in a salvage trial. </paragraph>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis and Other Post-Approval Trials in Adults  </content>
                        </paragraph>
                        <paragraph>In subsequent clinical trials in adult patients, non-susceptible isolates were recovered. <content styleCode="italics">S. aureus</content> was isolated from a patient in a compassionate-use trial and from 7 patients in the <content styleCode="italics">S. aureus</content> bacteremia/endocarditis trial <content styleCode="italics">[see <linkHtml href="#ID_16d8d2b7-9c07-4096-90d8-c314aba09824">Clinical Studies (14.2)</linkHtml>].</content> An <content styleCode="italics">E. faecium</content> was isolated from a patient in a vancomycin-resistant enterococci trial. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity </content>
                        </paragraph>
                        <paragraph>Daptomycin has been shown to be active against most isolates of the following microorganisms both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see <linkHtml href="#ID_fa1efd3e-c7f1-4dc0-be95-af6c70c261ba">Indications and Usage (1)</linkHtml>]. </content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">Gram-Positive Bacteria </content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible isolates only) </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus aureus</content> (including methicillin-resistant isolates) </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus agalactiae </content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus dysgalactiae </content>subsp<content styleCode="italics">. equisimilis </content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus pyogenes </content>
                           </item>
                        </list>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available, <content styleCode="underline">but their clinical significance is unknown</content>. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for daptomycin against isolates of similar genus or organism group. However, the efficacy of daptomycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials. </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">Gram-Positive Bacteria </content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Corynebacterium jeikeium </content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-resistant isolates) </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Enterococcus faecium</content> (including vancomycin-resistant isolates) </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus epidermidis</content> (including methicillin-resistant isolates) </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus haemolyticus </content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Testing  </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for daptomycin, please see: <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>. </paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b9e80e9b-3156-4da4-b2b7-34d8b1ccb631">
               <id root="b9e80e9b-3156-4da4-b2b7-34d8b1ccb631"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="ID_2fcf52ec-2194-4dac-83e1-e158fda114a5">
                     <id root="2fcf52ec-2194-4dac-83e1-e158fda114a5"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in animals have not been conducted to evaluate the carcinogenic potential of daptomycin for injection. However, neither mutagenic nor clastogenic potential was found in a battery of genotoxicity tests, including the Ames assay, a mammalian cell gene mutation assay, a test for chromosomal aberrations in Chinese hamster ovary cells, an <content styleCode="italics">in vivo</content> micronucleus assay, an <content styleCode="italics">in vitro</content> DNA repair assay, and an <content styleCode="italics">in vivo</content> sister chromatid exchange assay in Chinese hamsters. </paragraph>
                        <paragraph>Daptomycin did not affect the fertility or reproductive performance of male and female rats when administered intravenously at doses of 25, 75, or 150 mg/kg/day, which is approximately up to 9 times the estimated human exposure level based upon AUCs (or approximately up to 4 times the recommended human dose of 6 mg/kg based on body surface area comparison).</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0122b958-2bd3-4896-b78d-73125ad01158">
                     <id root="0122b958-2bd3-4896-b78d-73125ad01158"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Animals </content>
                        </paragraph>
                        <paragraph>In animals, daptomycin administration has been associated with effects on skeletal muscle. However, there were no changes in cardiac or smooth muscle. Skeletal muscle effects were characterized by microscopic degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). No fibrosis or rhabdomyolysis was evident in repeat-dose studies up to the highest doses tested in rats (150 mg/kg/day) and dogs (100 mg/kg/day). The degree of skeletal myopathy showed no increase when treatment was extended from 1 month to up to 6 months. Severity was dose-dependent. All muscle effects, including microscopic changes, were fully reversible within 30 days following the cessation of dosing. </paragraph>
                        <paragraph>In adult animals, effects on peripheral nerve (characterized by axonal degeneration and frequently accompanied by significant losses of patellar reflex, gag reflex, and pain perception) were observed at daptomycin doses higher than those associated with skeletal myopathy. Deficits in the dogs’ patellar reflexes were seen within 2 weeks after the start of treatment at 40 mg/kg/day (9 times the human C<sub>max</sub> at the 6 mg/kg/day dose), with some clinical improvement noted within 2 weeks after the cessation of dosing. However, at 75 mg/kg/day for 1 month, 7 of 8 dogs failed to regain full patellar reflex responses within a 3-month recovery period. In a separate study in dogs receiving doses of 75 and 100 mg/kg/day for 2 weeks, minimal residual histological changes were noted at 6 months after the cessation of dosing. However, recovery of peripheral nerve function was evident. </paragraph>
                        <paragraph>Tissue distribution studies in rats showed that daptomycin is retained in the kidney but appears to penetrate the blood-brain barrier only minimally following single and multiple doses. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animals </content>
                        </paragraph>
                        <paragraph>Target organs of daptomycin-related effects in 7-week-old juvenile dogs were skeletal muscle and nerve, the same target organs as in adult dogs. In juvenile dogs, nerve effects were noted at lower daptomycin blood concentrations than in adult dogs following 28 days of dosing. In contrast to adult dogs, juvenile dogs also showed evidence of effects in nerves of the spinal cord as well as peripheral nerves after 28 days of dosing. No nerve effects were noted in juvenile dogs following 14 days of dosing at doses up to 75 mg/kg/day. </paragraph>
                        <paragraph>Administration of daptomycin to 7-week-old juvenile dogs for 28 days at doses of 50 mg/kg/day produced minimal degenerative effects on the peripheral nerve and spinal cord in several animals, with no corresponding clinical signs. A dose of 150 mg/kg/day for 28 days produced minimal degeneration in the peripheral nerve and spinal cord as well as minimal to mild degeneration of the skeletal muscle in a majority of animals, accompanied by slight to severe muscle weakness evident in most dogs. Following a 28-day recovery phase, microscopic examination revealed recovery of the skeletal muscle and the ulnar nerve effects, but nerve degeneration in the sciatic nerve and spinal cord was still observed in all 150 mg/kg/day dogs. </paragraph>
                        <paragraph>Following once-daily administration of daptomycin to juvenile dogs for 28 days, microscopic effects in nerve tissue were noted at a C<sub>max</sub> value of 417 mcg/mL, which is approximately 3-fold less than the C<sub>max</sub> value associated with nerve effects in adult dogs treated once daily with daptomycin for 28 days (1308 mcg/mL). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Neonatal Animals </content>
                        </paragraph>
                        <paragraph>Neonatal dogs (4 to 31 days old) were more sensitive to daptomycin-related adverse nervous system and/or muscular system effects than either juvenile or adult dogs. In neonatal dogs, adverse nervous system and/or muscular system effects were associated with a C<sub>max</sub> value approximately 3-fold less than the C<sub>max</sub> in juvenile dogs, and 9-fold less than the C<sub>max</sub> in adult dogs following 28 days of dosing. At a dose of 25 mg/kg/day with associated C<sub>max </sub>and AUC<sub>inf</sub> values of 147 mcg/mL and 717 mcg•h/mL, respectively (1.6 and 1.0-fold the adult human C<sub>max</sub> and AUC, respectively, at the 6 mg/kg/day dose), mild clinical signs of twitching and one incidence of muscle rigidity were observed with no corresponding effect on body weight. These effects were found to be reversible within 28 days after treatment had stopped. </paragraph>
                        <paragraph>At higher dose levels of 50 and 75 mg/kg/day with associated C<sub>max</sub> and AUC<sub>inf</sub> values of ≥321 mcg/mL and ≥1470 mcg•h/mL, respectively, marked clinical signs of twitching, muscle rigidity in the limbs, and impaired use of limbs were observed. Resulting decreases in body weights and overall body condition at doses ≥50 mg/kg/day necessitated early discontinuation by postnatal day (PND) 19.  </paragraph>
                        <paragraph>Histopathological assessment did not reveal any daptomycin-related changes in the peripheral and central nervous system tissue, as well as in the skeletal muscle or other tissues assessed, at any dose level.  </paragraph>
                        <paragraph>No adverse effects were observed in the dogs that received daptomycin at 10 mg/kg/day, the NOAEL, with associated C<sub>max</sub> and AUC<sub>inf</sub> values of 62 mcg/mL and 247 mcg•h/mL, respectively (or 0.6 and 0.4-fold the adult human C<sub>max</sub> and AUC, respectively at the 6 mg/kg dose).</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_42a77b39-cacd-4eaa-bd36-50ce950b0660">
               <id root="42a77b39-cacd-4eaa-bd36-50ce950b0660"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="ID_366d5972-d3b9-444e-b848-38e05e6e08cb">
                     <id root="366d5972-d3b9-444e-b848-38e05e6e08cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Complicated Skin and Skin Structure Infections </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults with cSSSI</content>
                        </paragraph>
                        <paragraph>Adult patients with clinically documented complicated skin and skin structure infections (cSSSI) (Table 16) were enrolled in two randomized, multinational, multicenter, investigator-blinded trials comparing daptomycin for injection (4 mg/kg IV every 24h) with either vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g IV per day). Patients could switch to oral therapy after a minimum of 4 days of IV treatment if clinical improvement was demonstrated. Patients known to have bacteremia at baseline were excluded. Patients with creatinine clearance (CL<sub>CR</sub>) between 30 and 70 mL/min were to receive a lower dose of daptomycin for injection as specified in the protocol; however, the majority of patients in this subpopulation did not have the dose of daptomycin for injection adjusted.</paragraph>
                        <table width="100%">
                           <caption>Table 16. Investigator’s Primary Diagnosis in the cSSSI Trials in Adult Patients (Population: ITT)</caption>
                           <col width="23%"/>
                           <col width="25%"/>
                           <col width="26%"/>
                           <col width="26%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Primary Diagnosis</content>
                                 </th>
                                 <th align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Adult Patients (Daptomycin for Injection / Comparator</content>
                                    <footnote ID="_Ref42895021">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                    <content styleCode="bold">)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Study 9801 </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=264 / N=266</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Study 9901 </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=270 / N=292</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pooled </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=534 / N=558</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Wound Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>99 (38%) / 116 (44%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>102 (38%) / 108 (37%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>201 (38%) / 224 (40%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Major Abscess</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>55 (21%) / 43 (16%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>59 (22%) / 65 (22%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>114 (21%) / 108 (19%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Ulcer Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>71 (27%) / 75 (28%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>53 (20%) / 68 (23%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>124 (23%) / 143 (26%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Other Infection<footnote ID="_Ref42895054">The majority of cases were subsequently categorized as complicated cellulitis, major abscesses, or traumatic wound infections.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>39 (15%) / 32 (12%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>56 (21%) / 51 (18%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>95 (18%) / 83 (15%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>One trial was conducted primarily in the United States and South Africa (study 9801), and the second was conducted at non-US sites only (study 9901). The two trials were similar in design but differed in patient characteristics, including history of diabetes and peripheral vascular disease. There were a total of 534 adult patients treated with daptomycin for injection and 558 treated with comparator in the two trials. The majority (89.7%) of patients received IV medication exclusively. </paragraph>
                        <paragraph>The efficacy endpoints in both trials were the clinical success rates in the intent-to-treat (ITT) population and in the clinically evaluable (CE) population. In study 9801, clinical success rates in the ITT population were 62.5% (165/264) in patients treated with daptomycin for injection and 60.9% (162/266) in patients treated with comparator drugs. Clinical success rates in the CE population were 76.0% (158/208) in patients treated with daptomycin for injection and 76.7% (158/206) in patients treated with comparator drugs. In study 9901, clinical success rates in the ITT population were 80.4% (217/270) in patients treated with daptomycin for injection and 80.5% (235/292) in patients treated with comparator drugs. Clinical success rates in the CE population were 89.9% (214/238) in patients treated with daptomycin for injection and 90.4% (226/250) in patients treated with comparator drugs. </paragraph>
                        <paragraph>The success rates by pathogen for microbiologically evaluable patients are presented in <linkHtml href="#_Ref95305747" title="Table 17">Table 17</linkHtml>.</paragraph>
                        <table ID="_Ref95305747" width="100%">
                           <caption>Table 17. Clinical Success Rates by Infecting Pathogen in the cSSSI Trials in Adult Patients (Population: Microbiologically Evaluable)</caption>
                           <col width="63%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Success Rate n/N (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for Injection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnote ID="_Ref95305755">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses).</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Methicillin-susceptible <content styleCode="italics">Staphylococcus aureus </content>(MSSA)<footnote ID="_Ref95305791">As determined by the central laboratory.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>170/198 (86%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>180/207 (87%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Methicillin-resistant <content styleCode="italics">Staphylococcus aureus </content>(MRSA)<footnoteRef IDREF="_Ref95305791"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>21/28 (75%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>25/36 (69%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus pyogenes</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>79/84 (94%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>80/88 (91%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus agalactiae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>23/27 (85%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>22/29 (76%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus dysgalactiae </content>subsp.<content styleCode="italics"> equisimilis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8/8 (100%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>9/11 (82%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Enterococcus faecalis </content>(vancomycin-susceptible only)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>27/37 (73%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>40/53 (76%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (1 to 17 Years of Age) with cSSSI</content>
                        </paragraph>
                        <paragraph>The cSSSI pediatric trial was a single prospective multi-center, randomized, comparative trial. A total of 396 pediatric patients aged 1 to 17 years with cSSSI caused by Gram positive pathogens were enrolled into the study. Patients known to have bacteremia, osteomyelitis, endocarditis, and pneumonia at baseline were excluded. Patients were enrolled in a stepwise approach into four age groups and given age-dependent doses of daptomycin for injection once daily for up to 14 days. The different age groups and doses evaluated were as follows: Adolescents (12 to 17 years) treated with 5 mg/kg of daptomycin for injection (n=113), Children (7 to 11 years) treated with 7 mg/kg of daptomycin for injection (n=113), Children (2 to 6 years) treated with 9 mg/kg of daptomycin for injection (n=125) and Infants (1 to &lt;2 years) treated with 10 mg/kg (n= 45). </paragraph>
                        <paragraph>Patients were randomized 2:1 to receive daptomycin for injection or a standard of care (SOC) comparator, which included intravenous therapy with either vancomycin, clindamycin, or an anti-staphylococcal semi-synthetic penicillin (nafcillin, oxacillin, or cloxacillin). Patients could switch to oral therapy after clinical improvement was demonstrated (no minimum IV dosing was required).  </paragraph>
                        <paragraph>The primary objective of this study was to evaluate the safety of daptomycin for injection. The clinical outcome was determined by resolution or improvement of symptoms at the End-of-Treatment (EOT), 3 days after the last dose, and Test-of-Cure (TOC), 7-14 days after the last dose. Investigator observed outcomes were verified in a blinded fashion. Of the 396 subjects randomized in the study, 389 subjects were treated with daptomycin for injection or comparator and included in the ITT population. Of these, 257 subjects were randomized to the daptomycin for injection group and 132 subjects were randomized to the comparator group. Approximately 95% of subjects switched to oral therapy. The mean day of switch was day 4, and ranged from day 1 to day 14. The clinical success rates determined at 7–14 days after last dose of therapy (IV and oral) (TOC visit) were 88% (227/257) for daptomycin for injection and 86% (114/132) for comparator.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_16d8d2b7-9c07-4096-90d8-c314aba09824">
                     <id root="16d8d2b7-9c07-4096-90d8-c314aba09824"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults with <content styleCode="italics">S. aureus</content> Bacteremia/Endocarditis</content>
                        </paragraph>
                        <paragraph>The efficacy of daptomycin for injection in the treatment of adult patients with <content styleCode="italics">S. aureus</content> bacteremia was demonstrated in a randomized, controlled, multinational, multicenter, open-label trial. In this trial, adult patients with at least one positive blood culture for <content styleCode="italics">S. aureus</content> obtained within 2 calendar days prior to the first dose of study drug and irrespective of source were enrolled and randomized to either daptomycin for injection (6 mg/kg IV every 24h) or standard of care [an anti-staphylococcal semi-synthetic penicillin 2 g IV every 4h (nafcillin, oxacillin, cloxacillin, or flucloxacillin) or vancomycin 1 g IV every 12h, each with initial gentamicin 1 mg/kg IV every 8 hours for first 4 days]. Of the patients in the comparator group, 93% received initial gentamicin for a median of 4 days, compared with 1 patient (&lt;1%) in the daptomycin for injection group. Patients with prosthetic heart valves, intravascular foreign material that was not planned for removal within 4 days after the first dose of study medication, severe neutropenia, known osteomyelitis, polymicrobial bloodstream infections, creatinine clearance &lt;30 mL/min, and pneumonia were excluded. </paragraph>
                        <paragraph>Upon entry, patients were classified for likelihood of endocarditis using the modified Duke criteria (Possible, Definite, or Not Endocarditis). Echocardiography, including a transesophageal echocardiogram (TEE), was performed within 5 days following study enrollment. The choice of comparator agent was based on the oxacillin susceptibility of the <content styleCode="italics">S. aureus</content> isolate. The duration of study treatment was based on the investigator’s clinical diagnosis. Final diagnoses and outcome assessments at Test of Cure (6 weeks after the last treatment dose) were made by a treatment-blinded Adjudication Committee, using protocol-specified clinical definitions and a composite primary efficacy endpoint (clinical and microbiological success) at the Test of Cure visit. </paragraph>
                        <paragraph>A total of 246 patients ≥18 years of age (124 daptomycin for injection, 122 comparator) with <content styleCode="italics">S. aureus</content> bacteremia were randomized from 48 centers in the US and Europe. In the ITT population, 120 patients received daptomycin for injection and 115 received comparator (62 received an anti-staphylococcal semi-synthetic penicillin and 53 received vancomycin). Thirty-five patients treated with an anti-staphylococcal semi-synthetic penicillin received vancomycin initially for 1 to 3 days, pending final susceptibility results for the <content styleCode="italics">S. aureus</content> isolates. The median age among the 235 patients in the ITT population was 53 years (range: 21 to 91 years); 30/120 (25%) in the daptomycin for injection group and 37/115 (32%) in the comparator group were ≥65 years of age. Of the 235 ITT patients, there were 141 (60%) males and 156 (66%) Caucasians across the two treatment groups. In addition, 176 (75%) of the ITT population had systemic inflammatory response syndrome (SIRS) at baseline and 85 (36%) had surgical procedures within 30 days prior to onset of the <content styleCode="italics">S. aureus</content> bacteremia. Eighty-nine patients (38%) had bacteremia caused by methicillin-resistant <content styleCode="italics">S. aureus</content> (MRSA). Entry diagnosis was based on the modified Duke criteria and comprised 37 (16%) Definite, 144 (61%) Possible, and 54 (23%) Not Endocarditis. Of the 37 patients with an entry diagnosis of Definite Endocarditis, all (100%) had a final diagnosis of infective endocarditis, and of the 144 patients with an entry diagnosis of Possible Endocarditis, 15 (10%) had a final diagnosis of infective endocarditis as assessed by the Adjudication Committee. Of the 54 patients with an entry diagnosis of Not Endocarditis, 1 (2%) had a final diagnosis of infective endocarditis as assessed by the Adjudication Committee. </paragraph>
                        <paragraph>In the ITT population, there were 182 patients with bacteremia and 53 patients with infective endocarditis as assessed by the Adjudication Committee, including 35 with right-sided endocarditis and 18 with left-sided endocarditis. The 182 patients with bacteremia comprised 121 with complicated <content styleCode="italics">S. aureus</content> bacteremia and 61 with uncomplicated <content styleCode="italics">S. aureus</content> bacteremia. </paragraph>
                        <paragraph>Complicated bacteremia was defined as <content styleCode="italics">S. aureus</content> isolated from blood cultures obtained on at least 2 different calendar days, and/or metastatic foci of infection (deep tissue involvement), and classification of the patient as not having endocarditis according to the modified Duke criteria. Uncomplicated bacteremia was defined as <content styleCode="italics">S. aureus</content> isolated from blood culture(s) obtained on a single calendar day, no metastatic foci of infection, no infection of prosthetic material, and classification of the patient as not having endocarditis according to the modified Duke criteria. The definition of right-sided infective endocarditis (RIE) used in the clinical trial was Definite or Possible Endocarditis according to the modified Duke criteria and no echocardiographic evidence of predisposing pathology or active involvement of either the mitral or aortic valve. Complicated RIE comprised patients who were not intravenous drug users, had a positive blood culture for MRSA, serum creatinine ≥2.5 mg/dL, or evidence of extrapulmonary sites of infection. Patients who were intravenous drug users, had a positive blood culture for methicillin-susceptible <content styleCode="italics">S. aureus</content> (MSSA), had serum creatinine &lt;2.5 mg/dL, and were without evidence of extrapulmonary sites of infection were considered to have uncomplicated RIE. </paragraph>
                        <paragraph>The coprimary efficacy endpoints in the trial were the Adjudication Committee success rates at the Test of Cure visit (6 weeks after the last treatment dose) in the ITT and Per Protocol (PP) populations. The overall Adjudication Committee success rates in the ITT population were 44.2% (53/120) in patients treated with daptomycin for injection and 41.7% (48/115) in patients treated with comparator (difference = 2.4% [95% CI −10.2, 15.1]).  </paragraph>
                        <paragraph>The success rates in the PP population were 54.4% (43/79) in patients treated with daptomycin for injection and 53.3% (32/60) in patients treated with comparator (difference = 1.1% [95% CI −15.6, 17.8]). </paragraph>
                        <paragraph>Adjudication Committee success rates are shown in <linkHtml href="#_Ref95305878" title="Table 18">Table 18</linkHtml>.</paragraph>
                        <table ID="_Ref95305878" width="100%">
                           <caption>Table 18. Adjudication Committee Success Rates at Test of Cure in the S. aureus Bacteremia/Endocarditis Trial in Adult Patients (Population: ITT)</caption>
                           <col width="32%"/>
                           <col width="20%"/>
                           <col width="14%"/>
                           <col width="23%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Population</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Success Rate n/N (%)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <content styleCode="bold">Difference:</content>
                                    <br/>
                                    <content styleCode="bold">Daptomycin for </content>
                                    <br/>
                                    <content styleCode="bold">Injection –Comparator</content>
                                    <br/>
                                    <content styleCode="bold">(Confidence Interval)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Daptomycin for</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Injection 6 mg/kg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                       <footnote ID="_Ref95306333">Comparator: vancomycin (1 g IV every 12h) or an anti-staphylococcal semi-synthetic penicillin (i.e., nafcillin, oxacillin, cloxacillin, or flucloxacillin; 2 g IV every 4h), each with initial low-dose gentamicin.</footnote>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Overall</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>53/120 (44%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>48/115 (42%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>2.4% (−10.2, 15.1)<footnote ID="_Ref95306437">95% Confidence Interval</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Baseline Pathogen</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Methicillin-susceptible <content styleCode="italics">S. aureus</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>33/74 (45%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>34/70 (49%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>−4.0% (−22.6, 14.6)<footnote ID="_Ref95306477">97.5% Confidence Interval (adjusted for multiplicity)</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Methicillin-resistant <content styleCode="italics">S. aureus</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>20/45 (44%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>14/44 (32%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12.6% (−10.2, 35.5)<footnoteRef IDREF="_Ref95306477"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Entry Diagnosis<footnote ID="_Ref95306590">According to the modified Duke criteria5</footnote>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Definite or Possible Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>41/90 (46%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>37/91 (41%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>4.9% (−11.6, 21.4)<footnoteRef IDREF="_Ref95306477"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Not Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>12/30 (40%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>11/24 (46%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>−5.8% (−36.2, 24.5)<footnoteRef IDREF="_Ref95306477"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Final Diagnosis</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Uncomplicated Bacteremia</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>18/32 (56%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>16/29 (55%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.1% (−31.7, 33.9)<footnote ID="_Ref95306605">99% Confidence Interval (adjusted for multiplicity)</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Complicated Bacteremia</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>26/60 (43%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>23/61 (38%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5.6% (−17.3, 28.6)<footnoteRef IDREF="_Ref95306605"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Right-Sided Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8/19 (42%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>7/16 (44%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>−1.6% (−44.9, 41.6)<footnoteRef IDREF="_Ref95306605"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Uncomplicated Right-Sided Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>3/6 (50%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1/4 (25%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>25.0% (−51.6, 100.0)<footnoteRef IDREF="_Ref95306605"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Complicated Right-Sided Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>5/13 (39%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>6/12 (50%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>−11.5% (−62.4, 39.4)<footnoteRef IDREF="_Ref95306605"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <list listType="ordered">
                                       <item>
                                          <caption> </caption>Left-Sided Infective Endocarditis</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1/9 (11%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2/9 (22%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>−11.1% (−55.9, 33.6)<footnoteRef IDREF="_Ref95306605"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Eighteen (18/120) patients in the daptomycin for injection arm and 19/116 patients in the comparator arm died during the trial. These comprise 3/28 daptomycin for injection-treated patients and 8/26 comparator-treated patients with endocarditis, as well as 15/92 daptomycin for injection treated patients and 11/90 comparator-treated patients with bacteremia. Among patients with persisting or relapsing <content styleCode="italics">S. aureus</content> infections, 8/19 daptomycin for injection-treated patients and 7/11 comparator-treated patients died. </paragraph>
                        <paragraph>Overall, there was no difference in time to clearance of <content styleCode="italics">S. aureus</content> bacteremia between daptomycin for injection and comparator. The median time to clearance in patients with MSSA was 4 days and in patients with MRSA was 8 days. </paragraph>
                        <paragraph>Failure of treatment due to persisting or relapsing <content styleCode="italics">S. aureus</content> infections was assessed by the Adjudication Committee in 19/120 (16%) daptomycin for injection-treated patients (12 with MRSA and 7 with MSSA) and 11/115 (10%) comparator-treated patients (9 with MRSA treated with vancomycin and 2 with MSSA treated with an anti-staphylococcal semi-synthetic penicillin). Among all failures, isolates from 6 daptomycin for injection-treated patients and 1 vancomycin-treated patient developed increasing MICs (reduced susceptibility) by central laboratory testing during or following therapy. Most patients who failed due to persisting or relapsing <content styleCode="italics">S. aureus</content> infection had deep-seated infection and did not receive necessary surgical intervention <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_1ff93b2d-d382-4305-bd5d-25eeac00411f">Warnings and Precautions (5.9)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (1 to 17 Years of Age) with <content styleCode="italics">S. aureus</content> Bacteremia</content>
                        </paragraph>
                        <paragraph>The pediatric <content styleCode="italics">S. aureus</content> bacteremia study was designed as a prospective multi-center, randomized, comparative trial to treat pediatric patients aged 1 to 17 years with bacteremia. Patients known to have endocarditis or pneumonia at baseline were excluded. Patients were enrolled in a stepwise approach into three age groups and given age-dependent doses of daptomycin for injection once daily for up to 42 days. The different age groups and doses evaluated were as follows: Adolescents (12 to 17 years, n=14 patients) treated with daptomycin for injection dosed at 7 mg/kg once daily, Children (7 to 11 years, n=19 patients) treated with daptomycin for injection dosed at 9 mg/kg once daily and Children (2 to 6 years, n=22 patients) treated with daptomycin for injection dosed at 12 mg/kg once daily. No patients 1 to &lt;2 years of age were enrolled. </paragraph>
                        <paragraph>Patients were randomized 2:1 to receive daptomycin for injection or a standard of care comparator, which included intravenous therapy with vancomycin, semi-synthetic penicillin, first generation cephalosporin or clindamycin. Patients could switch to oral therapy after clinical improvement was demonstrated (no minimum IV dosing was required). </paragraph>
                        <paragraph>The primary objective of this study was to assess the safety of daptomycin for injection. The clinical outcome was determined by resolution or improvement of symptoms at test-of-cure (TOC) visit, 7 to 14 days after the last dose, which was assessed by the site level Blinded Evaluator. </paragraph>
                        <paragraph>Of the 82 subjects randomized in the study, 81 subjects were treated with daptomycin for injection or comparator and included in the safety population, and 73 had a proven <content styleCode="italics">S. aureus</content> bacteremia at Baseline. Of these, 51 subjects were randomized to the daptomycin for injection group and 22 subjects were randomized to the comparator group. The mean duration of IV therapy was 12 days, with a range of 1 to 44 days. Forty-eight subjects switched to oral therapy, and the mean duration of oral therapy was 21 days. The clinical success rates determined at 7 to 14 days after last dose of therapy (IV and oral) (TOC visit) were 88% (45/51) for daptomycin for injection and 77% (17/22) for comparator.</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5600abf3-739f-4a44-83a2-f7958a78f258">
               <id root="5600abf3-739f-4a44-83a2-f7958a78f258"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text/>
               <effectiveTime value="20220125"/>
            </section>
         </component>
         <component>
            <section ID="ID_76963578-b530-40d1-92f3-af4ede723ec3">
               <id root="94a15b86-597b-42c3-b929-777b8c799adc"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption> </caption>DAPZURA RT (daptomycin for injection) is supplied as a sterile pale yellow to light brown lyophilized powder in a single-dose 10 mL vial containing 500 mg of daptomycin: Package of 1 (NDC 60977-145-01).  The vial stopper is not made with natural rubber latex.</item>
                     <item>
                        <caption> </caption>Store original packages at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Storage conditions for the reconstituted and diluted solutions are described in another section of the prescribing information <content styleCode="italics">[see <linkHtml href="#ID_c33eb795-a4f9-495e-b82b-eb7031d3359d">Dosage and Administration (2.7)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20220125"/>
            </section>
         </component>
         <component>
            <section ID="ID_59ddb6f7-f791-4efc-bed8-dd02647c3236">
               <id root="27a4940c-fa38-4143-b91e-bcc673462a64"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that allergic reactions, including serious skin, kidney, lung, or other organ reactions, could occur and that these serious reactions require immediate treatment. Patients should report any previous allergic reactions to daptomycin. <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_a6c3b820-7d70-4676-a7b5-ffedb795d4ef">Warnings and Precautions (5.1</linkHtml>
                     </content>
                     <content styleCode="italics">, <linkHtml href="#ID_34392483-c75a-4134-88d5-b319eb7e75e7">5.4</linkHtml>, <linkHtml href="#ID_f031b9f5-753e-4827-9e0f-1249ff472e3e">5.5)</linkHtml>.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Muscle Pain or Weakness (Myopathy and Rhabdomyolysis, Peripheral Neuropathy)</content>
                  </paragraph>
                  <paragraph>Advise patients to report muscle pain or weakness, especially in the forearms and lower legs, as well as tingling or numbness. <content styleCode="italics">[see <linkHtml href="#ID_c061bf68-533b-412a-b863-c46a029cd062">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_318fce59-5f18-4f7c-b8b4-71cc4637d396">5.6)</linkHtml>.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Cough, Breathlessness or Fever (Eosinophilic Pneumonia)</content>
                  </paragraph>
                  <paragraph>Advise patients to report any symptoms of cough, breathlessness, or fever.<content styleCode="italics"> [see <linkHtml href="#ID_c66c6a0f-8070-42d0-b46e-29a9161999b5">Warnings and Precautions (5.3)</linkHtml>.]  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">
                        <content styleCode="italics">C. difficile</content>-Associated Diarrhea (CDAD)</content>
                  </paragraph>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials, including daptomycin for injection, that usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, including DAPZURA RT, patients can develop watery and bloody stools (with or without stomach cramps and fever), even as late as 2 or more months after having received the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible. <content styleCode="italics">[see <linkHtml href="#ID_18653154-083c-4ed0-8fb7-bd1c154a8030">Warnings and Precautions (5.8)</linkHtml>.]  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Patients with Hereditary Fructose Intolerance (HFI)</content>
                  </paragraph>
                  <paragraph>Inform patients and caregivers that DAPZURA RT contains sorbitol and can be life-threatening when administered to patients with hereditary fructose intolerance (HFI) <content styleCode="italics">[see <linkHtml href="#ID_90f73d7f-da84-466d-b9cd-9cb44a993ec5">Warnings and Precautions (5.11)</linkHtml>].</content> Inquire for symptoms of sorbitol, fructose and/or sucrose intolerance.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs, including DAPZURA RT, should be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When DAPZURA RT is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be administered exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DAPZURA RT or other antibacterial drugs in the future. </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                  </paragraph>
                  <paragraph>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Made in the USA</paragraph>
                  <paragraph>Baxter and Dapzura RT are trademarks of Baxter International Inc.</paragraph>
                  <paragraph>0719004045</paragraph>
               </text>
               <effectiveTime value="20220125"/>
            </section>
         </component>
         <component>
            <section ID="ID_dd53c316-b501-468d-9e01-71a2749cdbed">
               <id root="56d2da67-e54b-47f2-b3ba-6662ea977fdc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id-449010685" referencedObject="ID_6e6a2a89-7683-4291-b0d5-fc5f48ffe7cf">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>Barcode (FPO)</paragraph>
                  <paragraph>Use 10 mL <content styleCode="bold">Sterile</content> or <content styleCode="bold">Bacte-<br/>riostatic Water</content> for Injection<br/>for reconstitution only.</paragraph>
                  <paragraph>NDC 60977-<content styleCode="bold">145</content>-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20°C to 25°C (68°F<br/>to 77°F).</content> See package insert<br/>for Usual Dosage and storage<br/>of reconstituted and further<br/>diluted product.<br/>07-09-00-0427</paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DAPZURA RT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daptomycin for injection)<br/>500 mg per vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use</content>
                     <br/>Single-dose vial –<br/>Discard Unused Portion</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>Lot: (FPO)<br/>Exp.: (FPO)</paragraph>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id-2076269521" referencedObject="ID_1447d35b-a9b0-4273-9950-bced278a9c11"/>
                  </content>
                  <content styleCode="bold">
                     <renderMultiMedia ID="id299419264" referencedObject="ID_3f7cb9bc-a177-4abb-a992-890fd4b690cd">
                        <caption>Carton Label</caption>
                     </renderMultiMedia>
                  </content>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use <br/>Rx Only</content>
                     <br/>Single-dose vial – Discard Unused Portion</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>2D Barcode Location</paragraph>
                  <paragraph>
                     <content styleCode="bold">DAPZURA RT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daptomycin for injection)<br/>500 mg per vial</content>
                  </paragraph>
                  <paragraph>NDC 60977-<content styleCode="bold">145</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">DAPZURA RT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daptomycin for injection)<br/>500 mg per vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use</content>
                  </paragraph>
                  <paragraph>Reconstitute viral only with<br/>
                     <content styleCode="bold">Sterile Water</content> for Injection or<br/>
                     <content styleCode="bold">Bacteriostatic Water</content> for Injection.</paragraph>
                  <paragraph>Single-dose vial -<br/>Discard Unused Portion</paragraph>
                  <paragraph>1D Barcode<br/>(01) 20360977145017</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage:</content> See Prescribing<br/>Information.</paragraph>
                  <paragraph>This package contains one single-dose<br/>vial of sterile DAPZURA RT (daptomycin for<br/>injection) and one package insert.<br/>
                     <content styleCode="bold">Store at 20°C to 25°C (68°F to 77°F);</content>
                     <br/>excursions permitted to 15°C to 30°C<br/>(59°F to 86°F) [see USP controlled Room<br/>Temperature.] See package insert for<br/>storage of reconstituted and further<br/>diluted product.</paragraph>
                  <paragraph>Not made with Natural rubber latex</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                     <br/>Deerfield, IL 60015</paragraph>
                  <paragraph>Made in the USA</paragraph>
                  <paragraph>2VR500<br/>07-01-00-0894</paragraph>
                  <paragraph>3-6118-520</paragraph>
                  <paragraph>NDC 60977-<content styleCode="bold">145</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">DAPZURA RT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daptomycin for injection)<br/>500 mg per vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use</content>
                  </paragraph>
                  <paragraph>Reconstitute viral only with<br/>
                     <content styleCode="bold">Sterile Water</content> for Injection or<br/>
                     <content styleCode="bold">Bacteriostatic Water</content> for Injection.</paragraph>
                  <paragraph>Single-dose vial -<br/>Discard Unused Portion</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>FPO 2D Barcode location</paragraph>
                  <paragraph>See enclosed package insert for<br/>reconstitution instructions and complete<br/>information on dosage and administration.</paragraph>
                  <paragraph>DAPZURA RT (daptomycin for injection)<br/>contains 500 mg/vial of daptomycin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Reconstitute with 10 mL Sterile Water<br/>for Injection or Bacteriostatic Water for<br/>Injection to obtain a final concentration<br/>of 50 mg/mL.</content>
                  </paragraph>
                  <paragraph>Each vial also contains 238 mg sorbitol<br/>and 238 mg of mannitol. Sodium<br/>hydroxide and/or hydrochloric acid are<br/>used to adjust pH.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains no preservatives.</content>
                  </paragraph>
                  <paragraph>Note: Parenteral drug products should be<br/>inspected visually for particulate matter<br/>prior to administration.</paragraph>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <observationMedia ID="ID_6e6a2a89-7683-4291-b0d5-fc5f48ffe7cf">
                     <text>Daptomycin Representative Container Label  60977-145-01</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1447d35b-a9b0-4273-9950-bced278a9c11">
                     <text>Daptomycin Representative Carton Label  60977-145-01 1 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03 1 of 2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3f7cb9bc-a177-4abb-a992-890fd4b690cd">
                     <text>Daptomycin Representative Carton Label  60977-145-01 2 of 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04 2 of 2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>